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ABSTRACT OF DISSERTATION

ANGIOTENSIN II INDUCTION OF REGIONAL EFFECTS IN MURINE
VASCULATURE
The renin angiotensin system (RAS) exerts many diverse physiological
functions throughout the body, mediated by its effector peptide, angiotensin II
(AngII). AngII has been linked with a variety of different functions ranging from
the initiation of severe vascular pathologies, such as atherosclerosis and
abdominal aortic aneurysm (AAA), to mundane physiological processes of fluid
homeostasis, vascular contraction, and regulation of blood pressure. To provide
a potential link between these functions, an in-depth analysis of regional effects
of AngII on aortic vasculature was performed.
The studies presented in this dissertation tested the overall hypothesis of
whether regional changes exist in the vasculature in response to angiotensin II
(AngII). We first infused AngII into C57BL/6 animals and studied the aortic
morphology in detail. On first glance, we detected a thickening throughout the
aorta, with no overt changes from region to region. However, upon further
analysis, it was demonstrated that there was a region-specific aortic arch
hyperplasia, versus the hypertrophy in the remainder of the aorta. Through a
series of experiments, this hyperplasia was linked to the redox-mediated protein
Id3. Further analysis of the vasculature demonstrated AngII exerted aortic
contractions which were limited to the infrarenal aorta. These contractions were
mediated by the AT1b receptor subtype in the RAS. We also demonstrate that
AngII leads to suprarenal specific formation of AAA, which can be attenuated by
the deletion of specific innate immune mediator proteins, such as MyD88 and
TLR4. Overall, these data suggest many region-specific roles for AngII in the
aortic vasculature and provide many novel findings as to the cause of these
effects.

KEYWORDS: angiotensin II; atherosclerosis; abdominal aortic aneurysm; innate
immunity; aortic morphology
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Chapter One: Angiotensin II Effectiveness in Vascular Smooth Muscle
Cells
The renin angiotensin system (RAS) is a very complex system that
controls such physiological functions as blood pressure regulation, sodium
balance, and water retention. These actions are mediated via the RAS effector
octapeptide angiotensin II (AngII). AngII activation of angiotensin receptors (AT)
induces many actions in various tissues and organ systems, with the subsequent
signaling processes being tightly controlled and extremely complex in nature.
This peptide has emerged as a critical regulatory hormone controlling such
systems as the heart, brain, vasculature, and kidneys. Repeated and aberrant
signaling through these AT receptors can lead to pathological results in various
cell types. One of the most extensively studied cell types, with regard to AngII, is
the vascular smooth muscle cell (VSMC). This review will encompass a basic
overview of the RAS and the role of AngII in regulation of VSMC growth and
proliferation.
The Renin Angiotensin System

A. System Overview
The RAS is one of the most diverse and physiologically relevant
processes in the body. Most actions of the RAS are mediated through the
octapeptide hormone AngII. This eight amino acid peptide is a powerful
dipsogen and thus regulates thirst responses, as well as numerable other
responses, including: blood pressure, sodium balance, and sympathetic nervous
activity. The classic production of systemic AngII is mediated by the
angiotensinogen (Agt) to angiotensin I (AngI) to AngII pathway. Agt is formed in
the liver and is the only known precursor of the RAS. Agt is cleaved to the
decapeptide, AngI, by a circulating aspartyl protease renin, which is formed and
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secreted by granular cells in the juxtaglomerular apparatus of the kidney. This
AngI is subsequently cleaved to AngII via the dipeptidyl carboxypeptidase
angiotensin converting enzyme 1 (ACE1), which is localized to lung endothelial
cells. AngII can then be subsequently degraded via many pathways involving
aminopeptidases forming the products angiotensin III and IV (AngIII, AngIV).1-4
Many other functional peptides exist in the RAS. These peptides consist
of the vasodilatory Ang1-7 and precursor peptide Ang1-12. The 1-12 peptide is
an intermediate molecule derived directly from Agt and is thought to be another
substrate for the formation of Ang peptides.5,6 The vasodilatory peptide, Ang1-7,
is formed from conversion of AngI via the tissue specific endopeptidases
neprilysin, thimet oligopeptidase, and prolyl oligopeptidase.7,8 Furthermore, the
recently discovered carboxypeptidase enzyme angiotensin converting enzyme 2
(ACE2) has the ability to cleave one amino acid from AngII, resulting in
conversion and down regulation of AngII and subsequent up regulation of the
vasodilatory peptide Ang1-7.9 This data suggests many pathways in the RAS
compete with/for the production of AngII and also suggests that levels of AngII
are therefore directly controlled by the balance of endopeptidases, ACE, and
ACE2.10
While the above overview might seem simplistic, the RAS is much more
complex than originally described. The classic production of systemic AngII,
represented above, is also combined with local production of AngII in tissue
compartments. This local tissue RAS is present in the vasculature and is
suggested to contain many components of the RAS system, with the
controversial exception of renin.11,12 Studies have demonstrated ACE and Agt
protein and mRNA are present in vascular smooth muscle cells, endothelium,
and adventitial perivascular fat.11,13-17 These data suggest a prominent role of
smooth muscle cells in the propagation of the RAS.
B. Heterogeneity of Type I (AT1) Angiotensin Receptor
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The AT1 receptor is of the seven transmembrane superfamily of G-protein
coupled receptors (GPCRs) and mediates virtually all known physiological
functions of AngII in numerous cell targets distributed throughout the body. In
humans, the AT1 receptor contains 359 amino acids, is mapped to chromosome
3, and shares approximately 95% homology to rodent and bovine receptors.18-20
Reports suggested that another AT1 receptor existed in the human genome with
differences in 10 out of the 359 amino acids.21,22 Although the human AT1
receptor has an alternative splicing of exons 3 and 5, resulting in a functional
receptor with a 32 amino acid N-terminal extension,23 subsequent studies have
not confirmed the existence of a second AT1 receptor.24,25
While the human genome only contains one AT1 receptor, this receptor is
split into two subtypes in rats and mice. These receptor subtypes share 92%
homology at the nucleotide level and 95% homology of amino acid residues and
are characterized as AT1a (chromosome 17) and AT1b (chromosome 2).26-28 The
similarity in homology and localization to different chromosomes is hypothesized
to be the result of a gene duplication in evolutionary development.29 The two
subtypes have demonstrated similar ligand binding and activation properties and
are functionally and pharmacologically indistinguishable.30 However, differences
between the two receptors are evident in regard to tissue distribution,
chromosome location, and potential regulation.
AT1a and AT1b mRNAs transcripts have been identified in rat: kidney,
liver, lung, testes, adrenal, heart, aorta, brain, and pituitary glands. While the
AT1a is the critical receptor in a majority of these tissues, the AT1b is the major
subtype expressed in brain, testes, and adrenal gland.31-34 AT1a receptor
expression in mouse tissues are similar to the organ lists above with the addition
of ovaries and adipose. However, the mouse has a more punctate localization of
AT1b receptors showing transcripts confined to adrenal glands, testis, and brain.
35

Recent data also demonstrates a high concentration of AT1b receptors in

vascular smooth muscle, specifically the abdominal aorta and small resistance
vessels.36-38 The homology of these two receptor subtypes makes it difficult, if
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not impossible, to develop antibodies for protein differentiation of the AT1a
versus the AT1b receptor. Several investigators have developed dozens of
antibodies without successful discrimination of the two receptors (unpublished
data, personal communications).
Genetic ablation studies of AT1a and AT1b receptors have yielded some
insights into the similar and divergent functions of these homologous subtypes.
The ablation of AT1a leads to substantially lower basal systolic blood pressure
(SBP), and infusion with AngII results in undetectable increases in SBP.39-41
However, while this data does not suggest a role for the AT1b receptor in SBP,
when dose-dependent increases in SBP were induced in AT1a ablated mice,
subsequent administration of the AT1 antagonist losartan or candesartan
significantly decreased SBP 8mmHg, compared to controls.42 These data
suggest that while AT1a is the main mediator of blood pressure, the AT1b
receptor contributes minimally to pressor effects. Similarly, many studies with
AT1a receptor ablation suggest a compensatory role for the AT1b receptor.
AT1b receptors also compensate for the lack of AT1a in regards to smooth
muscle cell calcium mobilization.43 These studies are supported by the AT1a/b
double deficient animal, which demonstrates even lower SBP and a severe
pathological kidney dysfunction compared to mice only lacking the AT1a
receptor.44,45 One of the major differences of the AT1a and AT1b receptors is
particularly evident in the role of AngII-mediated vascular contractions. AngIIinduced aortic contractions are limited to the abdominal aorta, where significant
amounts of AT1b receptor transcripts are localized. Furthermore, AT1a receptor
deficiency contracts similarly to proficient mice, which is ablated by the addition
of losartan.46 This and recent data, showing AT1b receptor ablation significantly
down regulates AngII abdominal contraction, demonstrates a role of AT1b as the
sole mediator of aortic and resistance vessel contractions.37,38,47 Other studies
show differences between the AT1a and AT1b receptors in regards to
glucocorticoids,48 estrogen,31 dietary sodium regulation of AT1a receptors,49,50
and superoxide production,51 with the AT1a subtype demonstrating the majority
4

of changes versus the AT1b receptor.
Despite the aforementioned similarities and differences, definitive roles of
the AT1a and AT1b receptors remains incomplete and poorly understood in
current literature. A prominent amino acid difference exists in the cytoplasmic tail
of the AT1a and AT1b receptors, which could explain some of the differences in
function between the two subtypes. A role was delineated for the final
intracellular loop and cytoplasmic tail, of the AT1 GPCR, which required the
specific amino acid sequence (position 312-14) of tyrosine-phenylalanine-leucine
for essential coupling of the Gq-mediator protein to the cytoplasmic tail.52 This
tyrosine is though to be a critical site of phosphorylation for receptor associated
interactions. Specifically, a critical difference is found in amino acid 312 of the Cterminus which is present as an argenine in AT1b receptors and a tyrosine in
AT1a receptors. This Tyr to Arg switch leads to a ineffective Gq coupling and
activation site in AT1b receptors versus the AT1a subtype. This, and other,
known substitutions may represent the differences in the functionality of the
receptor subtypes, however, further examination of this hypothesis is required.
C. Type II (AT2) Angiotensin Receptors
The AT2 receptors, a second major isoform of AT receptors, are localized
to the X chromosome and are composed of 363 amino acids. Unlike the
homology between the AT1a and AT1b receptor subtypes, the AT2 receptor is
only 32% homologous to the AT1 receptors.53 Expression levels of AT2 are
maximal during fetal development, specifically developing fetal adrenal medulla,
brain, connective tissues, and the skeletal system. The expression levels of AT2
dramatically decrease at and after the time of birth and are expressed in limited
amounts in the medial vasculature, brain, heart, kidneys, adventitia, and adrenal
glands.54-56
While AT1 receptors perform most of the physiological signaling of the
RAS, AT2 receptors bind AngII and exhibit anti-proliferative, pro-apoptotic, and
5

vasodilatory effects in VSMCs, which can antagonize the actions of the AT1
receptor.57-61 Furthermore, AT2 receptor signaling activates tyrosine and
serine/threonine phosphatases, which can inhibit AT1 receptor signaling pathway
activation via dephosphorylation.62,63 It has also been demonstrated that AT1
antagonism occurs through interaction and dimerization of the AT1 and AT2
receptors resulting in dysfunctional AT1 receptor signaling.64
These data suggest the AT2 receptor can act as a potent antagonist to the
actions of AT1. However, numerous conflicts exist in the interpretation of AT2
studies and the function of this receptor in the RAS. One such example
demonstrated AT2 could initiate cardiac hypertrophy, independent of AngII, and
furthermore could not antagonize AT1 receptor initiation of similar hypertrophic
disease.65 Other reports suggest AT2 receptor degradation can be prevented
independent of AngII via a yet unidentified ligand, suggesting promiscuous ligand
binding sites.66 Therefore, more experimentation is needed before a specific role
for this receptor can be ascertained after fetal development.
Physiological Effects of AngII in Vascular Smooth Muscle Cells

A. Effects on Vascular Contraction
AT receptor activation via AngII activates a plethora of signaling pathways.
However, in the most simple terms, AngII signaling occurs through five major
pathways: GPCR pathways, NADPH oxidase production of reactive oxygen
species (ROS), Mitogen-Activated Protein Kinase pathways (MAPK), Receptor
tyrosine kinases, and nonreceptor tyrosine kinases. For the induction of vascular
contraction, the GPCR activation pathway is considered to be the most
important, while the remaining pathways are involved in more pathophysiological
functions, and will be discussed in the next section.
AngII vascular contraction is an extremely rapid event, which utilizes many
signaling cascades. When the GPCR AT1 receptors are activated by the agonist
6

AngII, subsequent coupling to the G" (q/11 and 12/13) and G$( complexes67
initiates the downstream effector phospholipases (PL), such as PLA2, PLC, and
PLD.68 Specifically, activation of PLC is considered one of the earliest and most
rapidly detectable events resulting from AngII stimulation of SMCs. Activation of
PLC leads to immediate up regulation of membrane bound diacylglycerol (DAG)
and soluble inositol-1,4,5-triphosphate (IP3) via hydrolysis of phosphatidylinositol4,5-bisphosphate (PtdInsP2)69-72. This effect is dependent upon AT1 receptors,
as the selective antagonist Losartan, inhibits hydrolysis of PtdInsP2. The
sarcoplasmic reticulum contains many IP3 receptors, which are stimulated by the
increase in IP3, leading to the opening of channels allowing for calcium to efflux
into the cytoplasmic space. Binding of this free cytoplasmic calcium to
calmodulin leads to activation of myosin light chain kinase (MLCK), which
subsequently phosphorylates myosin light chain resulting in actin and myosin
interaction and subsequent smooth muscle cell contractions.73-77 This IP3mediated calcium release is considered a first transient burst that is short lasting,
producing transient contractions. The signal is propagated by AngII-mediated
transmembrane calcium influx, which is speculated to occur via voltage-gated
channels and leads to sustained AngII-induced vasoconstriction of the smooth
muscle.78-82
The other important mediator for propagation of contractions is the
membrane bound DAG molecule, described above. The release of calcium,
combined with AngII upregulations of DAG and the presence of
phosphatidylserine, leads to the activation of protein kinase C (PKC). PKC is
implicated in both AngII-mediated vascular contractions and VSMC growth via
activation of Na+H+ exchanger, resulting in intracellular alkalinization, a potent
mediator of actin and myosin association.83-86 This alkalinization induces
vasoconstriction via increasing concentrations of sodium and calcium and by
sensitizing contractile machinery to calcium signals.77,87-90 It is important to note
that both AT1a and AT1b receptors are both implicated in the AngII induction of
intracellular calcium.43 Many other pathways exist in the initiation and
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propagation of contractions, such as AngII-mediated formation of leukotrienes
and cyclooxygenase-derived prostaglandins via PLA2 production of arachidonic
acid. However, it appears the IP3 and DAG-mediated contractions are the most
prominent.
The signaling pathways, listed above, lead to the final consequence of
SMC contraction. AngII effects on aortic contractile responses have provided
insight that the octapeptide has region-specific effects. Initial studies by Zhou et
al. demonstrated AngII-mediated contractions to be confined to the abdominal
aorta and the femoral artery, with weakened contraction in the carotid artery and
almost no signal in the thoracic aorta.36,46 Further, these studies demonstrated
that AT2 antagonism with PD123319 resulted in no change in AngII contractility,
while AT1 antagonism with Losartan resulted in full ablation of contraction. This
effect was correlated to an increase in AT1 mRNA expression in the abdominal
aorta. In a subsequent experiment, Zhou et al. provided a connection of this
contractile effect to the AT1b receptor using genetically ablated AT1a receptor
mice.36 The results demonstrated no change in contraction using the deficient
AT1a mice, however, the administration of Losartan ablated the contractile
signal. Further, mRNA analysis confirmed the up regulation of AT1b in the
femoral and abdominal aorta versus the thorax. Therefore, in mouse aortic rings,
AngII does not induce a contraction in thoracic tissue, but generates a large
transient contraction in abdominal tissue.36,46 Recent verification of this
pharmacological inhibition has been shown with the use of AT1b receptor
deficient animals displaying minimal to no AngII-induced contractions.47
Small resistance vessels have also been analyzed for their contractile
properties to stimulation with AngII. These resistance vessels are considered
crucial for mediation of vasoconstriction induction of hypertension to AngII.
Similar results to abdominal aortic contraction and femoral contractions Zhou et
al. demonstrated AngII-induced contractions in small mesenteric arteries and
found that the AT1b receptor accounted for 98% of AT1 expression.38 The
efferent and afferent arterioles of the renal microvasculature have also been
8

studied utilizing an in vitro measurement of afferent and efferent arteriolar
diameters (AAD and EAD). Results demonstrated no change in the AAD with the
ablation of the AT1a receptor, suggesting a role for the AT1b receptor. However,
AT1a deletion resulted in failure to elicit any change in EAD, when compared to
proficient animals, demonstrating a role for the AT1a receptor.91 These results
were later confirmed using AT1b receptor deficient animal demonstrating
functional expression of AT1a and AT1b on the afferent arterioles, and sole
functional expression of AT1a on the efferent arterioles.92 Combined with results
from complete AT1 deficient animals (double deficient AT1a and AT1b), these
results indicate that AT1a can also exhibit a contractile response in the
vasculature of the kidney.93 Therefore, a disparity still exists in the understanding
of AT1a and AT1b mediation of regional contractions, and further study is
needed.
As previously noted, aortic segments incubated with the AT2R antagonist
PD123319 resulted in normal AngII abdominal contractions.46 However, two
independent studies demonstrate an increased AngII induced contraction in
AT2R-/- animals.94,95 To confirm these results we obtained AT2R-/- animals and
incubated all four regions with AngII (unpublished data). We demonstrate no
difference in AngII infrarenal contraction with the AT2R-/- animals verifying the
studies of Zhou et al. Akishita et al. used thoracic aortas for their studies and
variable genetic background of their mice.94 Furthermore, Tanaka et al also
demonstrated increased contraction in AT2R-/- thoracic aortas.95 These results
are somewhat confounding since many groups demonstrate no reactivity to AngII
in thoracic aortic segments, including our results in three different genotypes.
B. Effects of AngII on Vascular Remodeling
Numerous studies are devoted to the study of AngII and subsequent
physiological and pathological effects on SMCs, both in vitro and in vivo. These
studies demonstrate AngII to be a powerful growth factor leading to mitogenic,
9

hypertrophic, apoptotic, and differentiation phenotypes in VSMCs.96 The
mediation of these various phenotypes is attributed to the cytokines or growth
factors present and the location of the VSMCs.97-99 These region-specific effects
may be due to the phenotypic diversity of aortic SMCs that arise as a
consequence of heterogeneity of embryological origin, as well as the cytokines
and growth factors present.97-99 SMCs in the ascending aortic regions are
primarily of neural crest origin, which extends from the aortic root to just distal of
the subclavian artery.100 This same lineage also extends to the carotid arteries.
Conversely, thoracic and abdominal aortic SMCs are derived from somite and
splanchnic mesoderm lineages, respectively. This may represent many of the
differences noted in the literature.
Most studies on cultured aortic SMCs have isolated cells from the thoracic
region of rats.97,98,101 In these cells, AngII consistently promotes
hypertrophy,67,97,101-109 with a lesser number of studies demonstrating a
proliferation response.98,110,111 The relative effects of AngII on hypertrophy versus
proliferation, in vitro, appear to depend on culture conditions, such as confluency
and the co-incubation with specific cytokines.98 The expression of the cyclindependent kinase inhibitor, p27kip1, in cultured cells is also a factor determining
the relative effect on hypertrophy versus proliferation.104 The AngII-induced
suppression of the cyclin dependent kinase (CDK) 2 lead to high levels of
p27kip1, leading to G1-phase arrest and cellular hypertrophy. Alternatively,
recent data also suggests AngII regulates inhibitor of differentiation (Id) proteins
2 and 3 via superoxide release.112-114 These Id proteins depress the activity of
p21WAF1/Cip1, p27KIP1, and p53, allowing for proliferation responses. Studies
demonstrate that the Id3 protein is highly overexpressed in vascular injury
models resulting in uncontrolled VSMC proliferation.112 These data suggest that
AngII can modulate hypertrophic situations by suppressing the cell cycle and
mitogenic conditions by allowing unimpeded cell-cycle progression.
Many AngII-induced responses on SMCs are also due to stimulation of
NADPH oxidase with the subsequent generation of ROS.115-117 These include
10

AngII-induced hypertrophy and proliferative responses, as noted above. NADPH
oxidase is a multimeric complex. SMCs express specific isoforms of gp91phox,
with nox1 being the principal regulator of AngII-induced responses.118-121 The
activity of nox1 is regulated by the presence of p47phox.122 Consistent with the
nox1-p47phox axis, deficiency of p47phox decreases AngII-induced increases in
systolic blood pressure.123
Lesser number of studies have chronically infused AngII in vivo to
determine effects on medial dimensions.124-126 SMC proliferative responses to
AngII infusion have been demonstrated in rat carotid and mesenteric arteries.127130

In contrast, the predominance of studies have demonstrated AngII increased

medial thickness through hypertrophy of rat124,125,127 and mouse121,126,131 aortas.
The location of aortic sections used in these studies has not been commonly
stated, but is likely to be the thoracic region. Recently unpublished data from our
laboratory presents region-specific aortic arch hyperplasia, versus hypertrophy in
the thoracic and suprarenal/infrarenal abdomen. These results were performed
in a mouse model of AngII infusion, and are consistent with the report of rat
studies in the carotid artery. Similar to this report, this effect was not due to
pressure, as norepinephrine infusion did not result in similar proliferative
responses to AngII. As previously stated, aortic arch and carotid SMCs are
derived from a neural crest lineage, while thoracic and abdominal cells are
derived from a somite and splanchnic mesoderm line of cells. This difference in
embryologic origin could explain the differences of SMC responsiveness to AngII.
Conclusions
The RAS is a complex collection of receptors that lead to the initiation of
numerous signaling cascades resulting in many physiological and pathological
consequences. Even with the vast knowledge of AngII signaling cascades and
resultant vascular functions and dysfunctions, these conflicting data suggest
many underlying processes involved in medial thickening and that the exact
11

mechanisms of arterial remodeling are as yet still undetermined. However,
consistently recurring themes seem to be the origin, the surrounding
environment, and regulation of cell cycle progression of AngII on VSMC to
determine the outcome of remodeling.

Copyright © Albert Phillip Owens III 2008
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Chapter Two. Angiotensin II Induction of Region-specific Morphology:
Angiotensin II Induces Region-specific Hyperplasia of the Ascending Aorta
Through Regulation of Inhibitor of Differentiation 3.

2.1 SYNOPSIS
Angiotensin II (AngII) promotes many changes in aortic tissue. The aim of
this study was to determine the nature of aortic medial changes during AngII
infusion and determine the role of blood pressure and oxidant mechanisms.
AngII (1,000 ng/kg/min) infusion for 28 days into mice increased systolic blood
pressure (SBP) and promoted medial expansion of equivalent magnitude
throughout the entire aorta. Both effects were ablated by AT1a receptor
deficiency. Similar increases in blood pressure by administration of
norepinephrine promoted no changes in aortic medial thickness. Increased
medial thickness was due to smooth muscle cell (SMC) expansion attributable to
hypertrophy in most aortic regions, with the exception of hyperplasia of the
ascending aorta. Deficiency of the p47phox component of NADPH oxidase
ablated AngII-induced medial expansion in all aortic regions. Analysis of mRNA
and protein throughout the aorta revealed a much higher abundance of the
inhibitor of differentiation 3 (Id3) in the ascending aorta compared to all other
regions. A functional role was demonstrated by Id3 deficiency inhibiting AngIIinduced SMC hyperplasia of the ascending aorta. In conclusion, AngII promotes
both aortic medial hypertrophy and hyperplasia in a region-specific manner via
an oxidant mechanism. The ascending aortic hyperplasia is dependent on Id3.
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2.2 INTRODUCTION
Angiotensin II (AngII) has many physiological and pathological effects on
smooth muscle cells (SMCs) of aortic tissue both in vitro and in vivo. Most
studies on cultured aortic SMCs have isolated cells from the thoracic region of
rats.97,98,101 In these cells, AngII consistently promotes hypertrophy,97,101 with a
lesser number of studies demonstrating a proliferation response.98 The relative
effects of AngII on hypertrophy versus proliferation, in vitro, appear to depend on
culture conditions, such as confluence and the co-incubation with specific
cytokines.98 The expression of the cyclin-dependent kinase inhibitor p27kip1, in
cultured cells, is a factor determining the relative effect on hypertrophy versus
proliferation.104
Many AngII-induced responses on SMCs are due to stimulation of NADPH
oxidase with the subsequent generation of reactive oxygen species (ROS).115-117
These include AngII-induced hypertrophy and proliferative responses. NADPH
oxidase is a multimeric complex. SMCs express specific isoforms of gp91phox,
with nox1 being the principal regulator of AngII-induced responses.118,119,121 The
activity of nox1 is regulated by the presence of p47phox.122 Consistent with the
nox1-p47phox axis, deficiency of p47phox blunts AngII-induced increases in systolic
blood pressure.123 More recently, the dominant-negative helix-loop-helix protein
(dnHLH), inhibitor of differentiation 3 (Id3), has been invoked as a regulator of
redox-mediated AngII induced proliferation.112,113
AngII effects on aortic contractile responses have provided insight that this
octapeptide has region-specific effects. AngII does not induce contractions of
mouse aortic rings isolated from thoracic tissue, but generates a large transient
contraction in abdominal tissue in vitro.132,133 Contractions of aortic rings are
mediated by AT1b receptors despite the presence of AT1a receptors, which may
be indicative of divergent signaling mechanisms stimulated by these
subtypes.15,16 Region-specific effects on aorta have been noted in response to
other bio-activators such as transforming growth factor-beta.134,135 These region14

specific effects may be due to the phenotypic diversity of aortic SMCs that arise
as a consequence of heterogeneity of embryological origin.99
AngII infusion, in vivo, is well known to promote changes in medial aortic
SMCs via mechanisms that are independent of increased SBP.129 The aim of the
present study was to determine whether AngII infusion in vivo promoted
heterogenous effects on SMC growth and/or proliferation throughout the entire
aorta. Despite previously described differences in contractile activity of AngII on
thoracic versus abdominal aorta,132,133 we were unable to demonstrate
morphological differences in these two regions during AngII infusion. However,
the ascending aorta has a different response than the rest of the aorta with a
medial expansion that was attributable to hyperplasia, versus hypertrophy in
other regions. Aortic medial expansion throughout the aorta was ablated by
deficiency of p47phox, while deficiency of Id3 inhibited the hyperplasia induced
by AngII in the ascending aorta.
2.3 Materials and Methods

Mice:
AT1a receptor deficient mice (N=10; B6.129P2-Agtr1atm1Unc; stock no.
002682), C57BL/6 (stock no. 000664), and p47phox mutant mice (B6(Cg)Ncf1m1J/J, stock no. 004742; backcrossed N $10 C57BL/6; C57p47/p47) were
purchased from the Jackson Laboratory. Littermate controls were utilized for all
experiments. Id3 -/- mice were a generous gift from Dr. Yuan Zhang (Duke
University), and were N $10 for the C57BL/6 background. Mice were housed in
a pathogen-free environment and fed a normal diet (Harlan Teklad catalog No.
2918) and water ad libitum. All studies were performed using male mice.
Genotyping for AT1a receptor-/- mice,136 C57p47/p47,137 and Id3-/-138 mice was
performed as described previously.1,2,3 All procedures were approved by the
University of Kentucky IACUC.
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Alzet Pump Implantation:
At 8 to 10 weeks of age, C57BL/6, AT1a receptor-/-, C57p47/p47, and Id3-/male mice were implanted with Alzet mini-osmotic pumps (Model 2004, Durect
Corp), subcutaneously in the right flank and infused with either sterile saline or
AngII (Sigma cat# A9525; 1,000 ng/kg/min) for 28 days (n = 5-10), as described
previously.139 In addition, norepinephrine (L-(-)-norepinephrine bitartrate salt
(NE), Sigma cat# A9512; 5.6 mg/kg/day) was infused into C57BL/6, AT1a
receptor-/-, and C57p47/p47 mice (n=5 each group).140 NE was dissolved in Lascorbic acid/saline (Fisher cat# A61; 0.2% wt/vol) as described previously.141
No Nitro-L-arginine methyl ester hydrochloride (Sigma cat# N5751) was
introduced via the drinking water at a concentration of 1.5 mg/ml (~100
mg/kg/day, changed daily).142
Systolic Blood Pressure Measurement:
SBP was measured noninvasively on conscious mice using the Visitech
tail cuff system (BP-2000 Visitech Systems). Mice were habituated 1.5 weeks
prior to pump implantations and SBP was measured 5-6 times a week, at the
same time of day, throughout the entire infusion period, as described
previously.142
Tissue Preparation:
Mice were anesthetized with ketamine/xylazine, blood was collected with
EDTA (0.2% wt/vol) from the right ventricle, and exanguination was performed
via an incision in the right atria. Aortas were perfused via the left ventricle with
phosphate-buffered saline and then perfusion fixed with paraformaldehyde (4%
wt/vol) under physiological pressure for 30-45 minutes. Organs were removed
and aortas were filled, via the left cardiac ventricle, with low melting point
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agarose (Promega cat# V2111; 3% wt/wt ) and colored with a green tissue dye
(Polysciences, Inc. cat# 24110), as described previously.143 Ascending aortic
sections were located 1 to 3 mm distal to termination of valve leaflet stubs.
Thoracic sections were located between 5 mm and 7 mm posterior of the left
subclavian artery. Suprarenal abdominal aortic sections were flush with the
superior mesenteric artery and 2 mm anterior. Infrarenal abdominal aortic
sections were 2 mm cut from the left renal branch to the posterior. These aortic
sections are schematically represented (Figure 2.1). Aortic sections were placed
in OCT (Tissue-Tek cat# 4583) and cut serially in 10 :m increments (posterior to
anterior) with 9 sections per slide and a total of 8 slides. With the exception of
ascending arch aortas (no branch points), all branch points and aortic vessels
were discarded, leading to the final coverage of approximately 900 to 1500 :m of
aorta per cross-sectional slide.
Morphometric Analyses:
Sections were stained with hematoxylin-eosin, mounted with
glycerol/gelatin (Sigma), and captured on a Nikon Optiphot-2 with a Nikon DXM
camera. The inner elastic lamina was traced and subtracted from the outer
elastic lamina to measure medial areas. Medial thickness was calculated from
means of 4 orthogonal measures of the distances between the internal and
external elastic lamina. Mean medial areas and thicknesses were measured from
5 to 15 sections per mouse. Measurements were performed using Image ProPlus 5.0 software (Media Cybernetics).
Nuclei Counting:
Frozen sections were fixed in paraformaldehyde (4% wt/vol). Propidium
iodide staining (Molecular Probes, P-3566, 1 :g/ml) was performed,
subsequently to RNA digestion for 15 min at 37°C. The nuclei counts were
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quantitated on 2 aortic segments of equivalent length (0.25 mm) per serial
section (minimum of 6 sections per slide).
Aortic Immunostaining and Histology:
Histological analysis was performed on paraformaldehyde fixed frozen
sections using Movat’s pentachrome (PolyScientific, cat# K042).
Immunostaining was performed on frozen serial sections as described
previously.144 An "-actin SMC antibody (5 :g/ml; Abcam, cat# ab5694) was
incubated for 30 minutes at 37°C.145 Subsequent application of a goat antirabbit
biotinylated antibody (1:500; Vector) was incubated for 30 minutes at 37°C.
Positive reactive areas were visualized via application of an ABC kit (10 minutes
37°C) and subsequent detection with AEC chromogen (2 applications of 10
minutes 37°C; Vector). Several controls were used, including: no primary
antibody, no primary and secondary antibodies, and non-immune sera or IgG
when appropriate.145 Images were captured with a 20x objective lens using a
Nikon Eclipse E600 scope and a Nikon DXM1200F digital camera.
SMC Isolation:
Aortas from 8-10 week old male C57BL/6J mice (Jackson Laboratory)
were isolated and dissected free of adventitia in serum-free Dulbecco’s Modified
Eagle’s Medium (DMEM). Aortas were divided into four sections: ascending
aorta (above the heart to left subclavian artery), thoracic aorta (left subclavian
artery to last intercostal artery), suprarenal aorta (last intercostal artery to right
renal artery), and infrarenal aorta (left renal artery to iliac bifurcation). SMCs
were isolated via chemical digestion using type III porcine pancreatic elastase
(250 :g/ml, Sigma) and type I collagenase (1 :g/ml, Worthington), as described
previously.146 SMCs were maintained in DMEM with fetal bovine serum (20%
vol/vol; FBS, Equitech, Inc.) and penicillin and streptomycin (1% wt/vol, Gibco) in
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a 37°C incubator with 5% CO2. SMC phenotype was determined via visualization
with Cy3 labeled "-actin clone 1A4 (Sigma).
Cellular Immunofluorescence and Confocal Microscopy:
SMCs were isolated as described above, and grown on glass Lab-Tek
chamber slides (Nunc) (n=6 separate samples each section). At 70%
confluence, cells were washed, and subsequently incubated with serum-free
media. After 72 hours, wells were rinsed with PBS, and incubated with either
saline or AngII (1 :M) for 1, 2, 12, and 24 hours. Slides were then rinsed with
PBS and fixed with paraformaldehyde (4% wt/vol) for 10 minutes. Cells were
permeabilized with Triton X-100 (0.5% vol/vol) in PBS for 10 minutes at 37°C.
Non-specific binding was blocked via incubation with normal goat serum (15

:g/ml) and BSA (1% wt/vol) for 30 minutes at 37°C. An rabbit monoclonal Id3
primary antibody (5 :g/ml; Cal Bioreagents, clone 6-1) was incubated overnight
in a humidity chamber at 4°C. After washing 3 times in PBS, secondary goat
antirabbit labeled Cy2 (1:250 dilution, Jackson Immuno) and Cy3-labeled "-SMC
actin (1:100 dilution, clone 1A4, Sigma) were added for 30 minutes at 37°C.
Chambers were subsequently washed 3 times with PBS and then incubated with
Hoechst 33342 (1 :g/ml; Invitrogen) for 5 minutes. Chambers were removed,
slides were mounted with aqueous mounting media (Biomeda Corp), and cover
slips were fixed in place using clear nail polish. Controls were included using no
addition of primary antibody, no addition of either primary or secondary
antibodies, and rabbit IgG control (5 :g/ml). Slides were visualized and captured
using an Olympus BX61WI confocal microscope and FluoView software.
SMC Proliferation Analyses:
SMCs were isolated, as described above, counted using a
hemacytometer, and seeded onto 35 x 10 mm culture wells at 10,000 cells/well.
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Separate primary harvests from 5 different groups of 8-10 week old male
C57BL/6 mice (Jackson Laboratory) were performed. Cells were immediately
serum-starved for 24 hours and then incubated with saline, AngII (1 :M), or
PDGF-BB (25 ng/ml; Sigma) for 24, 48, or 72 hours. Saline, AngII, or PDGF-BB
were incubated with cells in the presence of FBS (2.5% vol/vol; which did not
induce changes in cell numbers). Wells were washed 3 times using PBS and
cells removed using trypsin-EDTA (0.25% wt/vol; Gibco), quenched with FBS,
and subsequently counted using a hemacytometer. Cell numbers were also
verified on a Hemavet 950 (Drew Scientific) cell counter.
Dichlorodihydrofluorescein diacetate (DCF-DA) Analyses:
SMCs were isolated, as described above, plated on glass Lab-Tek
chamber slides, and grown to ~70-80% confluence in DMEM with FBS (20%
vol/vol; n=5 separate samples each section). Cells were then serum-starved for
24 hours in DMEM, and subsequently incubated with AngII (1 :M), AngII (1 :M)
+ losartan (1 :M), saline, H2O2 control (1 :M), or saline no DCF-DA blank
control. DCF-DA (Invitrogen) reagent was incubated with cells after 24 hours of
incubation. Chamber slides were subsequently visualized using a Nikon Eclipse
E600 scope with excitation sources and filters appropriate for fluorescein (FITC)
detection.
Amplex Red Analyses:
SMCs were isolated, as described above, plated on 6-well culture plates,
and grown to ~70-80% confluence in DMEM with FBS (20% vol/vol; n=4
separate samples each section). Cells were serum-starved for 24 hours and
incubated with saline, AngII (1 :M), or AngII (1 :M) + PEG-catalase (100 U/ml,
Sigma) for an additional 24 hours. Amplex red assay (Invitrogen) was performed
using modifications described previously in the protocol.147 Fluorescence
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intensity was determined using a microplate reader (Molecular Devices,
SpectroMax M2) in the excitation range of 530-560 nM and emission detection at
590 nm. SMCs were incubated with standard lysis buffer, protein was extracted,
and examined using a Bradford Assay (Bio-Rad). Fluorescent readings were
subsequently normalized to cellular protein content.
Renin Analyses:
Blood was collected in syringes filled with EDTA (0.2 M) and centrifuged at
2,000 rpm for 20 minutes for plasma collection. Renin concentrations in plasma
(8 :l) were measured by incubation with an excess of angiotensinogen (0.4 :M;
Sigma) in the presence of EDTA (0.02 M) for 30 min at 37°C. AngI generated
was quantified by RIA using a commercially available kit (Diagnostic Systems
Laboratories).148
Cell Culture and Western Blot Analyses:
SMCs were isolated, as described above, and plated on 6-well culture
plates in DMEM with FBS (20% vol/vol). Separate primary harvests from 3
different groups of 8-10 week old male C57BL/6 mice (Jackson Laboratory) were
performed. At ~70-80% confluence, wells were washed 3 times with PBS and
serum-starved for 72 hours, as described previously.149 Cells were then
incubated with either saline or AngII (1 :M) for 1, 2, 12, or 24 hours and total cell
lysates were extracted using 1x cell lysis buffer (cat: 9803; Cell Signaling) with
addition of protease inhibitor cocktails. Protein content was measured using a
Bradford Assay (Bio-Rad) and subsequently equal amounts of protein (20 :g)
were resolved using SDS-PAGE (12.5% wt/vol), and transferred via
electrophoresis (50 V for 90 minutes) to PVDF membranes (Millipore).
Membranes were blocked at room temperature with nonfat milk (5% wt/vol) in
Tris-buffered saline, containing tween 20 (0.5% vol/vol; TBS-T). Membranes
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were cut at the 25 kD molecular weight marker and the lower section was
incubated with an antibody against Id3 (0.5 :g/ml, clone 6-1, Cal Bioreagents).
The upper section was incubated with a $-actin antibody (1:1000, Sigma)
overnight at 4°C. Horseradish peroxidase-conjugated secondary antibodies were
incubated for 1 hour and immune complexes were visualized by a Supersignal
West Pico Chemiluminescence Kit (Pierce) and quantified using a Kodak Imager.
Real Time Polymerase Chain Reaction:
Ascending (aortic sinus to left subclavian), thoracic (left subclavian to last
intercostal), suprarenal (last intercostal to right renal), and infrarenal (left renal to
iliac bifurcation) sections of aortas were harvested from thirty 8 week old male
C57BL/6 and placed in RNA Later (Ambion, cat# 7024), and adventitia was
removed. Aortas were combined, in groups of 5, for a total of 6 independent
samples for each section. Aortas were ground with a glass mortar and pestle in
the presence of lysis buffer (Rneasy Fibrous Minikit Isolation System, Qiagen,
cat# 74704). All samples were incubated with Turbo DNA-free (Ambion, cat#
AM1907) to remove all DNA contamination. RNA concentrations were quantified
using a UV spectrophotometer (Beckman DU530). Reverse transcription of RNA
was performed with i-script (Bio-Rad, cat# 170-8891) with a concentration of 100
ng total RNA using an i-cycler (Bio-Rad). Real-time analysis of cDNA
amplifications were performed using a Bio-Rad i-cycler with Id3 Taqman probes
(Applied Biosystems, catalog# Mm00492575-m1) and IQ supermix (Bio-Rad,
cat# 170-8860). These results were compared to an 18s rRNA endogenous
control (Applied Biosystems, cat# 4352930E). Results were extrapolated using
the standard curve method with kidney serving as the Id3 standard. Negative
controls consisted of no RT controls and Id3-/- tissue cDNA, which was not
detectable with these primers. Another separate run was performed and stopped
in the middle of the sigmoidal real-time curve. These samples were run on a
agarose gel (3% wt/vol) diluted with a 6x blue-green running dye and molecular
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weight was analyzed with a PGEM DNA marker (Promega).
Statistics:
All statistical analyses were performed using either SigmaStat (SPSS Inc.)
or version 8.2 of SAS (SAS Institute). All measurements are represented as
means ± SEM. One Way ANOVA was performed on measurements, where
indicated, with a Holm-Sidak post hoc test. For two group comparison of
parametric data, a Student’s t-test was performed. Repeated measures data
were analyzed with SAS fitting a linear mixed model expressing the temporal
trend in systolic blood pressure as a quadratic polynomial in time for each
treatment. A Bonferroni-adjusted pairwise comparison was performed within
similar genotypes among treatments.
2.4 RESULTS

AngII infusion uniformly increased aortic thickening via AT1a receptors,
independent of pressure
AngII infusion (1,000 ng/kg/min) into C57BL/6 mice led to a sustained
increase in SBP (~40 mmHg) during the 28 days of delivery (Figure 2.2A). AngII
infusion also led to increased medial thickness and area to a similar percent in all
aortic regions (Figure 2.2B; Table 2.1). To determine the contribution of pressure
per se to medial expansion, NE was administered to male C57BL/6 mice at
doses that increased SBP by the same magnitude as AngII (approximately 40-50
mmHg). Contrary to AngII infusion, NE administration led to no significant
changes in medial thickness compared to age-, gender-, and strain-matched
mice infused with saline. Equivalent data were also obtained by increasing blood
pressure through administration of No-nitro-L-arginine methyl ester (L-NAME,
data not shown).
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To define whether AngII-induced medial thickening was mediated through
AT1a receptors, similar experiments were performed in AT1a receptor -/- mice.
Plasma renin concentrations were markedly increased in saline-infused AT1a
receptor -/- mice compared to C57BL/6 wild type controls (Table 2.1).
Interestingly, AngII infusion reduced plasma renin concentrations in both
C57BL/6 and AT1a receptor -/- mice. To determine if AT1b receptors mediated
effects of AngII to reduce plasma renin concentrations in AT1a receptor -/- mice,
we co-infused AngII and losartan. AngII-mediated reductions in plasma renin
concentrations were abolished in AT1a receptor -/- mice administered losartan.
AngII infusion failed to change SBP in AT1a receptor -/- mice (Figure 2.3A).
Moreover, infusion of AngII did not change aortic medial thickness or area in
AT1a receptor -/- mice (Figure 2.3B, Table 2.1). Infusion of NE increased SBP in
AT1a receptor -/- mice (Figure 2.3). However, NE infusion had no effect on
plasma renin concentrations or medial dimensions in any aortic region of AT1a
receptor -/- mice (Figure 2.3).
The basis of AngII-induced medial thickening differed among aortic regions
Medial thickening with AngII infusion was associated with a marked
expansion of the intra-laminar space in all aortic regions (Figures 2.4-2.5). This
expansion may potentially be attributable to contributions from extracellular
matrix expansion, and SMC hypertrophy or hyperplasia. To determine the
contribution of extracellular matrix (ECM), aortas were stained with Movat’s
pentachrome to permit visualization of elastin, collagen, and proteoglycans
(Figure 2.4). There were no overt differences in staining for ECM components.
Serial sections from all regions were immunostained for "-actin or stained with
propidium iodide to access expansion of cell size and number, respectively
(Figure 2.5). Immunostaining for "-actin demonstrated uniform reactivity
throughout the intra laminar spaces (Figure 2.5A). Negative controls
demonstrated no overt staining (Figure 2.6). Nuclei counts were normalized to a
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standard section length, since the medial expansion confounded the utilization of
vessel area. AngII infusion did not significantly affect nuclei density in both
thoracic and abdominal aortic regions (Figure 2.5B). When combined with data
from immunostaining, this was consistent with the medial expansion being due to
increased volume of SMCs. Unexpectedly, AngII promoted a marked increase in
nuclei density in tissue sections from the ascending aorta. Since this entire
region immunostained positively for SMCs, this was consistent with medial
expansion due to hyperplasia. AngII also exerted region-specific effects on
cultured SMCs. In agreement with the observations in vivo, AngII promoted a
proliferation of SMCs cultured from ascending aortas, but not in SMCs isolated
from other aortic regions (Figure 2.7). PDGF-BB promoted similar proliferation in
SMCs cultured from all aortic regions. Therefore, the basis for AngII-induced
medial expansion differed among aortic regions.
p47phox deficiency ablated AngII-induced medial thickness
Given the role of AngII-induced ROS on SMC hypertrophy and
hyperplasia, and the above region-specific data, we examined whether
concentrations of superoxide and hydrogen peroxide differed along the aorta. In
SMCs cultured from different aortic regions, there was uniform expression of
ROS in all aortic regions examined (Figure 2.8). To determine whether inability
to generate ROS resulted in functional changes in vivo, saline, AngII, or NE was
infused into mice with a spontaneous loss of function mutation for p47phox. Basal
blood pressure was not different between p47phox deficient mice compared to wild
type (C57BL/6). AngII infusion did not increase blood pressure initially in p47phox
functionally deficient mice (Figure 2.9), but did result in a belated increase during
week 4 of infusion. Plasma renin concentrations were unchanged in salineinfused p47phox deficient compared to wild type mice, and infusion of AngII led to
similar reductions in plasma renin concentrations in p47phox deficient mice. The
functional deficiency of p47phox had no effect on the ability of NE infusion to
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increase SBP (Figure 2.9A). The absence of functional p47phox abolished AngIIinduced increases in medial thickness for all regions of the aorta (Figure 2.9B).
AngII initiated Id3 translocation to nuclei
To provide a basis for AngII-induced medial SMC hyperplastic response
that was limited to the ascending portion of aortas, we defined the expression of
Id3. Real-time PCR analysis of Id3 mRNA demonstrated a significantly
increased (3.5 fold) abundance in ascending aortas versus other aortic regions
(Figure 2.10A). Western blotting of Id3 protein in cultured SMCs revealed similar
regional differences in the aorta (Figure 2.10B-D). As noted previously,149 Id3
abundance fluctuated over time in the presence of serum, but was always
greater in cells isolated from the ascending region. Furthermore, AngII incubation
of SMCs isolated from ascending aortas resulted in Id3 colocalization within
nuclei at 1 and 24 hours, with cycling to the cytoplasmic compartment at 12
hours (Figures 2.11-2.12). This effect was not observed in other aortic regions
(Figures 2.13). These data demonstrate AngII initiates cyclic Id3 localization to
the nuclei compartment, in the ascending aorta, suggesting a novel mechanisms
whereby id3 mediates the regional hyperplastic effects of AngII.
Id3 deficiency ablated ascending aortic hyperplasia
To determine the in vivo contribution of Id3 to AngII-induced ascending
aortic hyperplasia, Id3-/- mice were infused with either saline or AngII. AngII
markedly increased SBP in Id3-/- mice (Figure 2.14A). Furthermore, Id3
deficiency did not abolish AngII-induced increases of medial thickness in the
ascending and abdominal regions (Figure 2.14B). Similar to Id3+/+ mice,
immunostaining of aortas from Id3-/- mice with "-actin demonstrated uniform
reactivity throughout the intralaminar spaces and no overt matrix deposition by
Movats Pentachrome staining. Moreover, plasma renin concentrations were
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similarly reduced by AngII infusion in Id3-/- mice, compared to other mouse
strains (Table 2.1). SMC nuclei density was unchanged in other aortic regions
compared to wild type mice (data not shown). However, AngII-induced increases
in ascending aortic SMC nuclei density were strikingly reduced by Id3 deficiency
(Figure 2.15).
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Figure 2.1: Schematic diagram of analyzed regional aortic segments. The
left subclavian, superior mesenteric, and left renal arteries represent landmarks
for standardization between animals. Dashed yellow lines indicate cuts in the
aorta, while arrows represent direction of sectioning from start to finish.
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Figure 2.2: AngII-induced uniform medial expansion throughout the aorta,
independent of increased SBP. (A) SBP was measured prior to pump
implantation and every week during drug administration. Points represent the
mean of weekly observations (n=5) and bars represent SEM. * Denotes P <
0.0001 for AngII, NE, and L-NAME versus saline using repeated measures with
Bonferroni post-hoc. # Denotes P < 0.003 AngII versus NE and L-NAME week 4.
(B) Aortic medial thickness measured in arch, thoracic, supra-, and infrarenal
sections of C57BL/6 mice with saline, AngII, NE, and L-NAME. Histobars are
means of 5 - 10 mice and bars represent SEM. * Denotes P < 0.001 in AngII
infusion versus all other groups (one-way ANOVA with Holm Sidak post hoc).
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Figure 2.3: AngII infusion induced medial thickening via interaction with
AT1a receptors. (A) SBP was measured prior to pump implantation and every
week after drug administration in AT1a receptor -/- mice infused with saline,
AngII, or NE. Points represent the mean of weekly observations (n=5) and bars
represent SEM. * Denotes P < 0.0001 for NE versus saline or AngII using
repeated measures with Bonferroni post-hoc. (B) Medial thickness in 4 aortic
regions. Histobars represent means and bars represent SEM.
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Figure 2.4: AngII infusion results in no overt deposition of extracellular
matrix. Movat’s pentachrome staining of sections of aortas from mice infused
with either saline or AngII. The following denotes specific cellular content and
the visual color associated: muscle (red), ground substance (blue/green), elastin
fibers (black), collagen and reticulum fibers (yellow).
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Figure 2.5: AngII infusion induced medial thickness by either hypertrophy
or hyperplasia. (A) Representative C57BL/6 aortic sections of immunostaining
for "-actin. Tissue sections from ascending, thoracic, suprarenal, and infrarenal
aortic sections, infused with saline or AngII, were immunostained with a rabbit
anti-"-actin (1:200 dilution). (B) Nuclei density was determined by counting, and
normalized to aortic section length. Circles represent means of individual mice,
diamonds represent means of 5-10 mice in each group, and bars are SEM. *
Denotes P < 0.001 difference between saline or AngII-infused mice using a
Student’s t test. Examples of C57BL/6 saline (C) and AngII (D) infused aortic
arch sections stained with propidium iodide for nuclei identification.
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Figure 2.6: Control tissues for the SMC "-actin immunostaining. (Upper
Panel) No primary antibody control incubated with secondary antibody (1:500
dilution) only, (Middle Panel) no primary and no secondary antibody control,
(Lower Panel) Rabbit IgG control 5 :g/ml.
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Figure 2.7: AngII induces cellular proliferation in SMCs harvested from
ascending aortas. SMCs harvested from specific regions were seeded at day 0
with 10,000 cells/well, serum starved for 24 hours, and subsequently incubated
for 72 hours with saline, AngII (1 :M), or PDGF-BB (25 ng/ml). Histobars are
means of 5 individual experiments and bars represent SEM. * Denotes P <
0.001 for SMCs from ascending aortas incubated with either AngII or PDGF-BB
versus saline, and thoracic, suprarenal, and infrarenal PDGF-BB versus saline
and AngII (one-way ANOVA with Holm Sidak post hoc).
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Figure 2.8: AngII induces similar concentrations of ROS in SMCs from all
aortic regions. Ascending aortic SMCs were incubated with (A-B) saline, (C)
AngII (1 :M), or (D) AngII (1 :M) + losartan (1 :M) for 24 hours and
subsequently stained for DCF-DA (except for A). (E) Regional release of H2O2
was detected using an Amplex Red assay in SMCs incubated with saline, AngII
(1 :M), or AngII (1 :M) + PEG-catalase (100 U/ml) for 24 hours. Histobars are
means of 4 individual experiments and bars represent SEM. * Denotes P <
0.001 in AngII incubated cells versus all other groups (one-way ANOVA with
Holm Sidak post hoc).
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Figure 2.9: Functional deficiency of p47phox attenuated both AngII-induced
hypertrophy and hyperplasia. (A) SBP was measured prior to pump
implantation and every week during infusion with saline, AngII, or NE. Points
represent means of weekly observations (n=5) and bars represent SEM. *
Denotes P < 0.0001 for NE versus saline or AngII using repeated measures with
Bonferroni post-hoc. # denotes P < 0.01 for AngII versus saline infused mice.
(B) Effects of infusions on medial thickness in p47phox deficient mice in 4 aortic
regions. Histobars are means of 5 mice and bars represent SEM.
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Figure 2.10: Id3 was most abundant in SMCs of the ascending aortic
region. (A) Id3 mRNA abundance was quantified by real-time PCR. Histobars
are means of 3 mice and bars are SEM. * Denotes P < 0.001 for abundance in
ascending aorta versus all other regions (one-way ANOVA). Ascending,
thoracic, suprarenal, or infrarenal SMCs were serum-starved for 72 hours and
incubated with either saline or AngII (1 :M) for 1 (B), 12 (C), or 24 (D) hours.
Histobars represent Id3 protein abundance normalized to $-actin and are means
of 3 individual experiments with bars represent SEM. * Denotes P < 0.001 for
ascending aortic SMCs versus all other regions, while ** denotes P < 0.05 for
ascending aortic SMCs incubated with AngII versus saline at the 12 hour interval
(one-way ANOVA with Holm Sidak post hoc).
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Figure 2.11: Detection of Id3 mRNA and protein. (A) Gel electrophoresis of
Id3 mRNA the 4 aortic regions as indicated. Examples show mRNA resolved on
a 3% gel with Id3 (top) and 18s rRNA (bottom) from a qRT-PCR stopped in the
middle of the sigmoidal curve. Growth arrested SMCs from (B) ascending, (C)
thoracic, (D) suprarenal, and (E) infrarenal aortic segments were incubated with
either saline or AngII (1 :M) for 1, 2, 12, or 24 hours. Blots are representative
examples from each regional segment, with Id3 analysis (top) and $-actin
internal control (bottom). Id3-/- spleen lysate was used for specificity analysis of
the Id3 antibody.
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Figure 2.12: Control immunofluorescent staining in SMCs. Ascending
aortic SMCs were serum-starved for 72 hours, fixed, and visualized. Upper
images represent no Cy2 control, while the lower images represents basal
ascending Id3 abundance after serum starvation. SMCs were stained for nuclei
(Hoechst, blue), Id3 (green, right column only), and "-SMC actin (red). Merged
images are in the bottom panels with Id3 and "-SMC actin colocalization
represented by yellow.
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Figure 2.13: AngII induced nuclei localization of Id3 in SMCs harvested
from ascending aortas. Ascending aortic SMCs were serum-starved for 72
hours and incubated with AngII (1 :M) for 1 (upper images), 12 (middle images),
or 24 (lower images) hours. SMCs were stained for nuclei (Hoechst, blue), Id3
(green), and "-SMC actin (red). Images were merged, with Id3 and nuclei
colocalization represented by pale blue and Id3 and "-SMC actin colocalization
represented by yellow.
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Figure 2.14: Id3 is minimally expressed in thoracic and abdominal SMCs.
Thoracic (upper images), suprarenal (middle images), and infrarenal (lower
images) aortic SMCs were serum-starved for 72 hours and incubated with AngII
for 24 hours. SMCs were stained for nuclei (Hoechst, blue), Id3 (green), and "SMC actin (red). Merged images are represented in the bottom panels, with Id3
and "-SMC actin colocalization represented by yellow.
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Figure 2.15: Id3 deficiency did not attenuate AngII-induced increases in
SBP and medial thickness. (A) SBP was measured during AngII infusion in Id3
+/+ and -/- mice. Points represent means of weekly observations (n = 5) and
bars represent SEM. * Denotes P < 0.0001 for saline versus AngII infused mice
using repeated measures with Bonferroni post-hoc. (B) Aortic medial thickness
was measured in ascending and suprarenal aortic sections of Id3 deficient mice
infused with saline or AngII. Histobars are means of 6-7 mice and bars represent
SEM. * Denotes P < 0.001 for AngII versus saline infusion (one-way ANOVA
with Holm Sidak post hoc).
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2.16: Deficiency of Id3 ablated AngII-induced hyperplasia in ascending
aortas. (A) Nuclei density in ascending aortas from Id3 +/+ and -/- mice.
Circles represent means of individual mice, diamonds represent means of 4 - 5
mice in each group, and bars are SEM. * Denotes P < 0.001 for ascending
aortas from Id3 +/+ mice infused with AngII versus saline by Student’s t test.
Examples of saline (B) or AngII (C) infused Id3-/- mice ascending aortic sections
stained with propidium iodide.
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2.5

DISCUSSION
This study demonstrated that AngII promoted a uniform medial expansion

throughout the aorta. Despite the uniformity of the expansion, the underlying
cause differed in a region-specific manner. SMC hyperplasia occurred in the
ascending aorta, but SMC hypertrophy in all other aortic regions. This effect was
due to stimulation of AT1a receptors, but independent of increases in SBP.
AngII-induced medial expansion was ablated in all aortic regions in mice with
functional deficiency of p47phox, while the hyperplastic response localized to the
ascending aorta was inhibited by deficiency of Id3.
AngII-induced medial expansion has the potential to be attributable to both
cellular and extracellular components. While AngII is known to increase several
ECM proteins, including collagen150,151 and proteoglycans152,
Therefore, this study
focused on the contributions of increases in cellular components to medial
expansion. Many studies have demonstrated that AngII promotes
hypertrophy97,101 of cultured aortic SMCs, with a lesser number demonstrating
proliferation.98 Most of these studies have been performed with SMCs that have
been derived from rat thoracic aorta. A lesser number of studies have chronically
infused AngII in vivo to determine effects on medial dimensions.124-126 SMC
proliferative responses to AngII infusion have been demonstrated in rat carotid
and mesenteric arteries.127-130 In contrast, the predominance of studies have
demonstrated AngII increased medial thickness in vivo through hypertrophy of
rat124,125,127 and mouse121,126,131 aortas. The location of aortic sections used in
these studies has not been commonly stated, but is likely to be the thoracic
region. Thus, the description of medial expansion being attributable to
hypertrophy in the thoracic aorta is consistent with the present study. However,
heterogeneity of AngII-induced responses within the aorta has not been
described previously. Our studies demonstrated that AngII-induced proliferation
was limited to SMCs cultured from the ascending aorta versus other aortic
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regions. However, the present study did not discern whether the in vivo increase
in nuclei was attributable to proliferation or polyploidization, although the
magnitude of the increase in nuclei in the ascending aorta is much larger than
has been described for polyploidization.124,153-155
The basis for the heterogeneous cause of AngII-induced medial expansion
in different regions of the aorta may be attributable to the diversity of embryonic
origin of SMCs with potential functional differences.99 SMCs in the ascending
aortic regions are primarily of neural crest origin, which extends from the aortic
root to just distal of the subclavian artery.100 This same lineage also extends to
the carotid arteries. Conversely, thoracic and abdominal aortic SMCs are
derived from somite and splanchnic mesoderm lineages, respectively. Regional
differences in aortic SMCs have been described previously.99
Deficiency of AT1a receptors ablated AngII-induced medial expansion in
all regions. Previous studies have highlighted the role of the AT1b receptor
subtype in aortic function.43,132 Although both “a” and “b” subtypes of AT1
receptors are expressed in the mouse aorta, deficiency of the “b” subtype
substantially reduced AngII-induced contractions that are restricted to the
abdominal aorta.133 Although the two subtypes are highly homologous, the
differences are predominantly in the final intracellular loop and the cytoplasmic
tail of this seven membrane spanning protein.156 These amino acid substitutions
have predictive differences on intracellular signaling.157,158 Thus, in future
studies, the relative differences between the subtypes will provide insight into the
definition of the intracellular pathway that leads to medial expansion.
As with previous studies, absence of AT1a receptors had no effect on
basal SBP in mice on a C57BL/6 background.41,136,159 Moreover, AT1a receptor
deficiency increased plasma renin concentrations, demonstrating removal of
AngII-mediated negative feedback on renin synthesis and secretion.44 This
maintenance of pressure is probably due to the continued presence of AT1b
receptors, since compound deficiency of both subtypes promotes a severe
phenotype as occurs with deficiency of angiotensinogen, renin, or ACE.160 The
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presence of functional AT1b receptors can be inferred in the present study by the
downregulation of plasma renin concentrations during AngII infusion into AT1a
receptor deficient mice and its reversal during concomitant infusion of the AT1
receptor antagonist, losartan.
Numerous studies have demonstrated a functional role of ROS,
specifically superoxide (O2 C-) and hydrogen peroxide (H2O2), in both hypertrophic
and hyperplastic responses of SMCs.105,112,113,131 AngII-induced production of O2
C-

and H2O2 has the potential to increase redox signaling pathways. However, we

were unable to demonstrate any regional differences in ROS production. A
major source of ROS during AngII stimulation of SMCs is via augmentation of
NADPH oxidase activity as demonstrated both in studies in cultured
SMCs105,115,161 and in vivo.121,126,131 NADPH oxidases are multimeric complexes
with components that differ in a cell-specific manner. In regard to AngII-induced
responses in SMCs, these are mediated by a complex containing nox1 in which
p47phox is a critical component for activation.122 The importance of this coupling
has been shown using gp91ds-tat which is a peptide that inhibits the assembly of
Nox1 with p47phox.162 Gp91ds-tat inhibits AngII-induced increases in SBP and
medial expansion of carotid arteries. Conversely, deficiency of p47phox attenuates
AngII-induced increases in SBP.123,163 In contrast to results from the present
study, a previous study demonstrated that p47phox deficiency increased basal
blood pressure, even though AngII-induced increases in SBP were attenuated.164
Moreover, those p47phox deficient mice show basal increases in renin,164 which we
were not able to demonstrate. Differences in results may arise from the mode of
interference with p47phox, since the previous study used genetically engineered
p47phox deficient mice, while the present study used p47phox deficient mice that
arose from a spontaneous mutation.165 However, although the spontaneous and
engineered mutations are on exon 8 and 7, respectively, there is no obvious
basis for these mice exhibiting different manifestations of deficiency. The
engineered p47phox deficient mice have been shown previously to exhibit no
change in basal SBP. However, other studies have demonstrated a greater
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effect on SBP during AngII infusion than in the current study.123,166 This greater
efficacy of AngII-induced increases in SBP may be a consequence of the use of
the [Val5] variant of AngII which has a greater efficacy at stimulating AT1
receptors compared to the AngII sequence of human and mouse peptides.
Irrespective of these differences among studies, the current study demonstrated
that deficiency of p47phox ablated aortic medial expansion in all regions.
AngII-induced proliferation of cultured SMCs occurs via activation of
NADPH oxidase with generation of superoxide production that subsequently
induces the expression of the dnHLH protein, Id3.112,113 Id3 dimerizes with the
bHLH factor E47, inhibits E47-induced activation of expression of cyclin
dependent kinase inhibitor p21WAF1/Cip1, and promotes SMC proliferation.149 This
mitotic effect is mediated via nuclei translocation of Id3, from the cytoplasm, via
an E47 nuclear localization signal (NLS).167,168 Id3 has also been implicated in
proliferative responses to carotid artery injury.169 As noted earlier, the carotid
artery shares common embryonic origin with cells in the ascending aorta.99,100 In
agreement with the disparity of the ascending aorta versus other aortic regions,
Id3 mRNA and protein abundance was much greater in this region. In contrast to
previous reports using rat thoracic SMCs, AngII had no observed effects in
upregulation of Id3 protein levels in mouse SMCs.113 However, we demonstrate
that AngII signaling can initiate Id3 localization to the nuclei compartment at 1
and 24 hours. Previous data demonstrated Id3 was upregulated and
phosphorylated at these intervals in correlation with cell cycle progression.149
Furthermore, direct evidence of a role of Id3 in the hyperplastic response was
derived from mice with genetic deficiencies of this protein. Although there is the
potential for Id3 deficiency to lead to compensatory increases of other Id
proteins, the total ablation of AngII-induced hyperplasia of the ascending aorta
provided a striking demonstration of the specific requirement for Id3. Moreover,
effects of Id3 deficiency on AngII-induced proliferative responses were observed
despite a marked increase in the blood pressure response to AngII, supporting
pressure-independent effects of AngII on SMC proliferation.
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In summary, this study demonstrated that AngII infusion promotes aortic
medial expansion by disparate mechanisms in a region-specific manner. A major
difference was the demonstration of the disparity of responses in the ascending
aorta compared to other regions. Unique responses of this region in aortic
lumenal expansion have also been demonstrated in mice harboring fibrillin-1
mutations that were infused with AngII.170 Although this study defined AngIIinduced changes in SMCs, this effect could be directly on SMCs or indirectly
from another cell type. For example, endothelial cells secrete a wide range of
products that directly affect SMC function. Recent data implicate PDGF-DD
secretion from endothelial cells as a moderator of SMC phenotypic modulation,
particularly in areas of disturbed blood flow, such as the aortic arch.171 Thus,
subsequent studies will determine the contribution of SMC and endothelial cells
to the observed phenotypes by using Cre-Lox technology to promote cell-specific
AT1a receptor deficiency.

Copyright © Albert Phillip Owens III 2008

49

Chapter Three: Angiotensin II and Region-specific Contractility: Infrarenal
Localization of AT1b Receptors Perpetuates Angiotensin II Vascular Aortic
Contractions.

3.1

Synopsis:

Background – Angiotensin II (AngII) promotes region-specific contraction in the
abdominal aorta. The aim of this study was to definitively determine the receptor
mediating this response and to further define this regional contractile response.
Materials and Methods – C57BL/6 aortas were segmented into 4 regions (aortic
arch, thoracic aorta, suprarenal aorta, and infrarenal aorta) and treated with
physiological agonists: potassium chloride (KCl, 80mM), 5-hydroxytryptamine (5HT, 1:M), and AngII (1:M). Equivalent contractile responses were
demonstrated with KCl and 5-HT, while AngII only induced a contraction in the
infrarenal abdominal aorta. Angiotensin receptor subtype 1A (AT1aR),
angiotensin receptor subtype 1b (AT1bR), and angiotensin receptor subtype 2
(AT2R) mRNA expression was examined via real-time PCR. All subtypes were
concentrated in the infrarenal abdominal aorta, with AT1bR demonstrating a 19
fold increase over the other two receptor subtypes. To verify the receptor
responsible for infrarenal-specific contraction of AngII, AT1aR deficient mice
(AT1aR-/-), AT1bR-/-, and AT2R-/- mice were examined. The absence of the
AT1aR and AT2R did not change AngII induction of abdominal contraction.
However, AT1bR-/- mice demonstrated complete ablation of infrarenal
contraction to AngII.
Conclusions: – AngII induces infrarenal-specific abdominal aortic contractions
mediated exclusively via the AT1bR.
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3.2

Introduction:
Angiotensin II (AngII) is the main effector peptide of the renin angiotensin

system, regulating blood pressure and fluid/electrolyte homeostasis.172 Several
receptor subtypes exist for engaging AngII, most notably AT1 and AT2 receptors.
In particular, the AT1 receptor is subdivided into two homologues in rodent
models: AT1a receptor and AT1b receptor.26-28 These two receptors share 94%
homology, however, have been shown to demonstrate different functional
properties as well as differential expression throughout the vasculature.36,46,172
Genetically manipulated models have been used to ascertain the role of
Ang receptors in murine models. AT1a receptor deficient (AT1aR-/-) mouse
studies show the preponderance of AngII-induced vascular pathology and blood
pressure regulation is mediated through this receptor subtype.39,42,44,173 The AT1b
receptor (AT1bR) performs a minimal role in these functions, however, roles for
this receptor subtype have been indirectly shown for AngII-induced vascular
smooth muscle cell contractile responsiveness.36,38,46 These responses are
region-specific and located in the abdominal aortic region and small resistance
vessels. The large aortic vessel displays embryologic heterogeneity complicating
the specificity of this effect.99,100 Furthermore, the divergent responses mediated
through these two receptor subtypes may contribute to these region-specific
effects.
This study defines regional contractile responses along the large vessel of
the aorta and ascertains the specific receptor subtypes responsible. In order to
definitively link the AT1bR to this abdominal contractile response, we used aortas
obtained from AT1bR-/- animals.
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3.3

Materials and Methods:

Mice:
Male AT1aR-/- mice in a C57BL/6 (B6) background (B6.129P2Agtr1atm1Unc; stock no. 002682) and male C57BL/6 (stock no. 000664) mice were
obtained from the Jackson Laboratory (Bar Harbor, ME). The AT1b receptor -/(AT1bR-/-) mice were a generous gift from Dr. Thomas Coffmann (Duke
University). The AT2 receptor -/- (AT2R-/-) mice were a generous gift from Dr.
Inagami (Vanderbuilt University). All mice were 10 times backcrossed in a
C57BL/6 background and were housed in a pathogen-free environment and fed a
normal diet (Harlan Teklad catalog No. 2918) and water ad libitum. Genotyping
for AT1aR-/-, AT1bR-/-, and AT2R-/- mice was performed as previously
described.44,95,145
Solutions and Chemicals:
Two solutions were prepared for incubation with aortic sections. Krebs
Henseleit physiologic solution was composed of: 123mM NaCl, 15.5mM
NaHCO3, 1.2mM MgSO4A7H2O, 1.25mM CaCl2, 11.5mM Dextrose, and 4.7mM
KCl. Krebs Henseleit KCl contraction solution was similar to the physiologic
solution, listed above, except NaCl was excluded, and KCl was increased to
80mM. All solutions were contained in heated reservoirs (37°C) and were
aerated with oxygen. The addition of CaCl2 was performed after 20 minutes of
incubation at 37°C, with aeration, as this chemical was difficult to dissolve. AngII
(Sigma and Baxter) and 5-hydroxytryptamine (5-HT, Sigma) was dissolved in
sterile deionized water (1mM) and 5:l was added to 50ml incubation baths of
physiologic solution for a final concentration of 1:M. All chemicals were
purchased from Fisher Scientific or Sigma and were of the highest grade
commercially available.46,174
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Tissue Preparation:
Mice were anesthetized with ketamine/xylene and exanguinated via
ligation of the right atria. Aortas were perfused, via the left ventricle, with
phosphate-buffered saline, removed, and then adventitia was carefully dissected
free. Measurement of contractile activity was performed using aortic rings as
described previously 174. Aortas were stripped free of endothelial cells by
passing a pair of serrated forceps over the aortic lumen. Aortic arch (3 mm),
upper thoracic aorta (4 mm), middle thoracic aorta (4 mm), lower thoracic aorta
(4 mm), suprarenal abdominal aorta (4 mm), and infrarenal abdominal aorta (4
mm) segments were mounted by passing two tungsten wires through the arterial
lumen and immersed in Krebs Henseleit solution. Tension (1 gm) was maintained
continuously and recorded on a Micro-Med instrument. After 30 min for
equilibration, tissues were incubated with KCl (80 mM, Sigma), 5-HT (1 :M,
Sigma), and AngII (1 :M, Sigma) with 30 minutes of recovery between each
agonist. Studies with the AT1aR-/- (n=10) and AT2R-/- (n=8) mice were
conducted in tandem with B6 controls allowing for no deviation in regard to buffer
or sample preparation. Studies with the AT1bR-/- (n=5) mice were conducted in
tandem with littermate controls, bred in-house.
Real Time Polymerase Chain Reaction:
Ascending (aortic sinus to left subclavian), thoracic (left subclavian to
last intercostal), suprarenal (last intercostal to right renal), and infrarenal (right
renal to iliac bifurcation) sections of aortas were harvested from 30 C57BL/6 and
placed in RNA Later (Ambion, cat# 7024), and adventitia was removed. Aortas
were combined, in groups of 3, for a total of 10 independent samples for each
section. Aortas were ground with a glass mortar and pestle in the presence of
lysis buffer (Rneasy Fibrous Minikit Isolation System, Qiagen, cat# 74704). All
samples were incubated with Turbo DNA-free (Ambion, cat# AM1907) to remove
53

all DNA contamination. RNA concentrations were quantified using a UV
spectrophotometer (Beckman DU530). Reverse transcription of RNA was
performed using i-script (Bio-Rad, cat# 170-8891) with a concentration of 100 ng
total RNA on a i-cycler (Bio-Rad). Real-time analysis of the cDNA was
performed using a Bio-Rad i-cycler and AT1aR taqman probe (Applied
Biosystems, catalog# Mm00616371_m1), AT1bR taqman probe (Applied
Biosystems, catalog # Mm01701115_m1), AT2R taqman probe (Applied
Biosystems, catalog # Mm01341373_m1) and IQ supermix (Bio-Rad, cat# 1708860). These results were compared to an 18s rRNA endogenous control
(Applied Biosystems, cat# 4352930E). Results were extrapolated using the
standard curve method with adrenal glands serving as the standards. Negative
controls consisted of no RT controls.
Statistics:
All statistics were performed using SigmaStat (SPSS Inc.). All
measurements are represented as the mean ± SEM. One Way ANOVA was
performed on all measurements with a Holm-Sidak post hoc test.
3.4

Results:

AngII incubation induced region-specific contractions in the infrarenal
abdominal aorta
Literature on the regional role of AngII aortic contractions is limited to the
broadly described thoracic and abdominal segments. To further define the
contribution of AngII in regional contractile responses, B6 aortas were
segmented into four regions (arch, thorax, suprarenal, and infrarenal abdomen).
Similar responses to KCl (80mM) and 5-HT were observed in all regions of the
aorta (Figure 3.1A-E). However, AngII (1:M) treatment of aortic sections
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resulted in a marked contraction in only the infrarenal aorta (Figure 3.1D-E). As
previously noted, AngII-induced contractions were transient resulting in a
tachyphylactic response in all aortic regions (Figure 3.1A-D).
Angiotensin receptor expression is basally concentrated in the infrarenal
aorta
To provide a basis for AngII-induced contractions, which were limited to
the infrarenal aorta, AT1a receptors, AT1b receptors, and AT2 receptors were
analyzed by real-time PCR. Analysis of AT receptor subtypes demonstrated
augmented mRNA expression in the abdominal (suprarenal and infrarenal)
regions of the aorta (Figure 3.2A-C). AT1aR expression in the infrarenal aorta
was increased 13 (arch), 34 (thoracic), and 2.5 (suprarenal) fold compared to the
other regions of the aorta (Figure 3.2A). AT1bR infrarenal mRNA was
upregulated 35, 9, and 3 fold (Figure 3.2B), while infrarenal AT2R expression
was upregulated 6, 22, and 4 fold versus the other regions of the aortic
vasculature (Figure 3.2C). The expression of AT1bR mRNA was increased 19
fold over AT1aR and AT2R in the infrarenal aorta.
AT1bR is the sole mediator of AngII-induced regional contractions
The above results suggest the AT1bR is highly concentrated in the
infrarenal segment of the aorta versus other receptor subtypes. This, and other
correlative data indirectly links AT1b receptors to AngII-induced contractility. To
definitively determine whether this receptor subtype is responsible for AngIImediated contraction, AT1aR-/-, AT1bR-/-, and AT2R-/- mice aortic regions were
assessed. When extrapolated to 80mM KCl, AT1aR-/- mice were not
significantly different from wild-type control animals when treated with agonists 5HT or AngII (Figure 3). The infrarenal aortic segments in AT1aR+/+ (78 ± 13%)
and -/- (74 ± 14%) mice produced a robust and similar contractile response.
Similarly, the AT2R-/- animals were unchanged from AT2R+/+ mice when treated
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with these agonists, including the AngII-induced infrarenal contraction (+/+: 116 ±
28%; -/-: 105 ± 14%). However, while the response to 5-HT was unchanged
between AT1bR genotypes, the AngII-induced infrarenal contraction was
completely ablated in the AT1bR-/- mice (0%) versus +/+ animals (99 ± 18%,
Figure 3.4).
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Figure 3.1: Angiotensin II induced region-specific contractions in the
infrarenal aorta. Representative recordings of maximal 80mM KCl contractions,
and percent maximal contraction to KCl for 5-HT and AngII for (A) aortic arch, (B)
thoracic aorta, (C) suprarenal abdominal aorta, and (D) infrarenal abdominal
aorta. I-bars underneath graph represent point of agonist stimulation (left bar)
and washing (right bar) of aortic tissues. (E) 5-HT (1:M) and AngII (1:M)
values expressed as percentage of maximal contraction compared to 80mM
KCL. Histobars are means of 14 mice and bars represent SEM. *Denotes
P<.001 in AngII infrarenal aorta versus all other AngII aortic groups (one-way
ANOVA with Holm Sidak post hoc).
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Figure 3.2: AT receptors are regionally concentrated in the infrarenal
abdomen. (A) AT1a, (B) AT1b, (C) AT2 receptor real-time mRNA expression
levels in the four regions of the aorta. Values were extrapolated from an adrenal
gland standard curve, where final values for specific receptor subtypes were
extrapolated from an 18s rRNA internal control. Histobars represent the means
of 10 samples and bars are SEM. *Denotes P<.008 in infrarenal aorta versus all
other aortic groups (one-way ANOVA with Holm Sidak post hoc). **Denotes
P<.001 in suprarenal AT1b expression versus aortic arch and thoracic aortic
regions.
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Figure 3.3: AngII-induced regional contractions are unchanged in AT1aR-/aortas. 5-HT (1:M) and AngII (1:M) values expressed as percentage of
maximal contraction compared to 80mM KCL within genotype controls.
Histobars are means of 5 mice and bars represent SEM. *Denotes P<.001 in
AngII infrarenal AT1aR+/+ and -/- aortas versus all other AngII aortic groups
(one-way ANOVA with Holm Sidak post hoc). No difference existed between
genotypes in the AngII-treated infrarenal aorta.
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Figure 3.4: AngII-induced regional contractions are ablated by AT1bR
deficiency. 5-HT (1:M) and AngII (1:M) values expressed as percentage of
maximal contraction compared to 80mM KCL within genotype controls.
Histobars are means of 5 mice and bars represent SEM. *Denotes P<.001 in
AngII infrarenal AT1bR+/+ aortas versus all other AngII aortic groups (one-way
ANOVA with Holm Sidak post hoc).
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Figure 3.5: AngII-induced regional contractions are unchanged in AT2R
deficiency. 5-HT (1:M) and AngII (1:M) values expressed as percentage of
maximal contraction compared to 80mM KCL within genotype controls.
Histobars are means of 5 mice and bars represent SEM. *Denotes P<.001 in
AngII infrarenal AT2R+/+ and -/- aortas versus all other AngII aortic groups (oneway ANOVA with Holm Sidak post hoc). No difference existed between
genotypes in the AngII-treated infrarenal aorta.

63

3.5

Discussion:
This study demonstrated that AngII promotes region-specific contractions

limited to the infrarenal aortic vasculature. To examine the molecular basis of
this effect, angiotensin receptors were quantified and found to be concentrated in
the infrarenal aorta, with AT1bRs being the most abundant. AngII-induced
infrarenal contractions were ablated only in the AT1bR-/- mouse defining this
receptor subtype as the sole mediator of murine aortic contractions.
Studies have linked AngII-induction of contractions to the abdominal
region of the aorta, however, an in-depth analysis of contractile function along
the aorta has not yet been examined.36,38,46 Therefore, the aorta was divided into
four regions: aortic arch, thoracic aorta, suprarenal aorta, and infrarenal aorta.
Contraction to physiological agonists KCL and 5-HT were unchanged in all aortic
segments, suggesting no generalized decrease in smooth muscle function
between different regions. However, AngII incubation mediated only infrarenalspecific contractions, when extrapolated to KCL. In order to verify this effect, the
aorta was divided into 7 aortic segments, consisting of: arch, upper thoracic,
middle thoracic, lower thoracic, suprarenal, infrarenal, and suprailiac aortic
vessels (unpublished). AngII-induced aortic contractions were limited to the
infrarenal and suprailiac aortas, suggesting sole localization of contractions
below the right renal vessel.
AngII abdominal contractile response has been indirectly linked to AT1bRs
by using pharmacological inhibition of AT1 receptors with the antagonist losartan
in AT1aR-/- animals.36 AT1aR-/- had a similar response to AT1aR+/+ animals
demonstrating this subtype does not mediate AngII abdominal contraction, in
accordance with previous literature. To directly link AT1bRs to AngII-induced
abdominal contraction, AT1bR-/- animals were obtained and aortic function
examined. Contraction to KCl and the agonist 5-HT were unchanged between
aortic regions in AT1bR+/+ and -/- animals demonstrating no loss of smooth
muscle cell function between genotypes. However, incubation of AT1bR-/64

infrarenal aortas with AngII resulted in total ablation of the contractile response
elicited in the other genotypes, verifying the studies using pharmacologic
inhibition. Interestingly, the AT1aR, AT1bR, and AT2R mRNA expression was
most abundant in the infrarenal aorta, with AT1bR being the most highly
expressed. Abundance of AT1aR in the infrarenal suggests presence of the
receptor and combined with AT1aR-/- results definitively demonstrates this
receptor does not mediate AngII contractions. However, conflicting data exists
for the AT2R in AngII aortic contractility.94,95
Previous studies with aortic segments incubated with the AT2R antagonist
PD123319 resulted in normal AngII abdominal contractions.46 However, two
independent studies demonstrate an increased AngII induced contraction in
AT2R-/- animals.94,95 To confirm these results we obtained AT2R-/- animals and
incubated all four regions with AngII. We demonstrate no difference in AngII
infrarenal contraction with the AT2R-/- animals verifying the studies of Zhou et al.
Akishita et al. used thoracic aortas for their studies and mice with variable
genetic backgrounds.94 Furthermore, Tanaka et al also demonstrated increased
contraction in AT2R-/- thoracic aortas.95 These results are somewhat
confounding since many groups demonstrate no reactivity to AngII in thoracic
aortic segments, including the results in three different genotypes presented
here.
Definitive roles of the AT1a and AT1b receptors remains incomplete and
poorly understood in current literature. Numerous studies demonstrate disparate
roles for these two receptor subtypes, which share 94% amino acid sequence
homology.172 Despite the similarities in these receptor subtypes, the differences
are predominantly found in the final intracellular loop and cytoplasmic tail of this
G-protein coupled receptor. A critical difference is found in amino acid 312 of the
C-terminus which is present as an argenine in AT1b receptors and a tyrosine in
AT1a receptors.52 This Tyr to Arg switch leads to a ineffective Gq coupling and
activation site in AT1b receptors versus the AT1a subtype. This, and other,
known substitutions may represent the differences in the functionality of the
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receptor subtypes.
While this manuscript was being prepared, Swafford et al. reported similar
ablation of AngII-induced contractions with AT1bR-/- animals.47 Unlike previous
publications by Zhou et al., this study was forthcoming with aortic ring locations
being near the iliac branch of the abdominal aorta.47 On the contrary, our studies
focus on the region-specificity of this effect being localized to the entire region of
the abdominal aorta, below the renal arteries, thereby reporting a novel regional
effect.
Although this study defined a specific role for the AT1bR in AngII-induced
contraction, the mechanism and signaling underlying this response is undefined.
Functional evidence suggests AT1a receptors mediate effects through direct
action on smooth muscle cells (postjunctional), while AT1b receptors mediate
effects through indirect facilitation of norepinephrine on smooth muscle.175 Other
studies provide a possible cross-talk pathway between alpha and beta adrenergic
receptors, which mediate norepinephrine signaling, and AT1 receptors.176 Thus,
subsequent studies will examine the role of alpha/beta adrenergic receptors and
their ability to cross-link with AT1b receptors in AngII-induced murine aortic
contractions.
In summary, this study demonstrated that AngII incubation of aortic
sections lead to a robust and regional contraction localized solely to the
infrarenal vasculature. This response was directly propegated from smooth
muscle cells and did not involve endothelial cells. This study provides direct
evidence that AT1bRs mediate this contraction through disparate mechanisms to
the homologue, AT1a.
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Chapter Four: Involvement of Innate Immunity in Angiotensin II-induced
Vascular Disease

Synopsis
Angiotensin II (AngII) infusion into hyperlipidemic animals results in the
formation of atherosclerosis and abdominal aortic aneurysm (AAA). As these
two vascular disease processes initiate and progress, they accumulate a variety
of inflammatory cell infiltrates mainly representative of the innate immune
system. Ablation of macrophages, mast cells, neutrophils, and natural killer cells
has been examined in one or both of these models and results consistently
demonstrate attenuation of disease progression. This is a comprehensive
analysis of these ablation studies.
Introduction
Atherosclerosis and AAAs are both characterized as chronic inflammatory
diseases resulting from the accumulation of immune cells, most notably
macrophages, at the site of injury.177,178 The identification and subsequent
characterization of these immune cells has led to the overall hypothesis of
immune modulation of atherosclerosis, to which the same conclusions can
applied to AAAs.168,171,179,180 Experiments using genetically altered animals and
manipulations of cultured cells have confirmed this process of immune
modulation of disease. To date, immune responses have been described in
every stage of atherosclerosis and AAAs, in both mice and men. This review will
attempt to summarize AngII-induced vascular disease (focused on
atherosclerosis and AAA) processes and the subsequent involvement of innate
immunity in the initiation of pathology.
Angiotensin II Vascular Disease (Special focus on atherosclerosis and
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AAA)

Atherosclerosis
Atherosclerosis is the leading cause of death in the western world. This
chronic disease is characterized by lesion formation, composed of lipids,
platelets, smooth muscle cells, macrophages (foam cells), T and B lymphocytes,
and matrix material that accumulates slowly over time.178 This cellular
accumulation leads to a narrowing of the blood vessels causing restricted blood
flow, which can lead to thrombus, ischemic stroke, or coronary occlusion.
Angiotensin II (AngII) is the primary bioactive peptide of the reninangiotensin system (RAS) and plays physiologic roles in regulation of blood
pressure and fluid balance.172 AngII activates AT1 receptors (AT1a in mice) to
induce most of its physiological effects. Infusion of AngII into hyperlipidemic
mice has recently been shown to augment atherosclerotic pathology.139,181 This
AngII-induced atherosclerosis is rapid and consists mainly of lipid-laden
macrophages and lymphocyte accumulation, similar to the diet-induced
pathology.139,182,183 A possible complication of this effect is the noted increase in
systolic blood pressure induced by AngII.184 However, concomitant studies with
norepinephrine and subpressor doses of AngII, have demonstrated these effects
of AngII are not pressor dependent.182,184,185
Abdominal aortic aneurysm (AAA)
AAA is a devastating and silent pathology that effects 5-10% of the male
population over the age of 65 and is listed as the 13th leading cause of death in
the United States.186,187 AAA, defined as a permanent localized dilation in the
arterial wall with a diameter greater than 50% of normal,188 is an inflammatory
disease that can result in the dissection of the aortic wall and eventual rupture.177
Surgical intervention at late stages of expansion is currently the only utilized
treatment, as no pharmacological therapy is currently available.189
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It has recently been demonstrated that infusion of AngII into
hyperlipidemic mice induces the formation of AAAs localized to the suprarenal
portion of the aorta. In comparison to human AAA data, the AngII model is
similar in elastin fiber destruction, intimal stability, proteolytic destruction of
medial connective tissues, inflammation, and increased incidence in the male
gender.148,177,190,191 An interesting difference is in the location of the aneurysm,
which is suprarenal in mice, but infrarenal in humans. However, murine AAA
formation is also localized to the suprarenal aorta, independent of AngII infusion,
in genetic ablation studies with LRP and iNOS, and in long term hyperlipidemic
animals.188,192-195 Therefore, this suggests that mouse AAA localization to the
suprarenal aorta may be due to hemodynamic factors in relation to the
quadruped nature of mice versus the biped nature of humans.188 This effect,
however, has been demonstrated to be independent of blood pressure using
subpressor doses of AngII and hydralazine-induced pressure ablation
studies.185,190,196 AngII-induced AAA formation is remarkably consistent and has
been reproduced by many laboratories.183,185,196,197
The progression of AngII-induced AAA formation has been described in
detail by examination of tissue sections at predetermined intervals.177 The first
observable event is the accumulation of macrophages into the tunica media of
the suprarenal aorta occurring between 1 to 3 days after infusion. This
accumulation is speculated to give rise to inflammatory cytokines and matrix
degrading enzymes, as medial elastin destruction and Lumenal expansion soon
ensues. The subsequent break in medial elastin appears to be contained by a
rapidly thickened adventitial layer surrounding the vessel. This containment
forms the rapid development of an intramural thrombolitic region, which becomes
fibrous and accumulates macrophages and other inflammatory cell types over
time. The aneurysm then gradually expands over time, and eventually leads to
regions of thinning and changes in histology.198
Comparing and contrasting atherosclerosis and AAA
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Atherosclerosis and AAA share similar beginnings in regards to arterial
expansion. For instance, both disease states initially expand the vessel in a
process referred to as outward arterial remodeling. In atherosclerotic disease,
this outward expansion is a compensatory response for increased accumulation
of macrophages, lipids, and other inflammatory cells (plaques) in the
lumen.178,199,199,200 Eventually, this outward remodeling achieves an as yet
unidentified limit, at which point the vessel expansion turns inward leading to
progressive occlusion of the vessel. In contrast, aneurysmal expansion of the
vessel does not turn inward, but instead continues expanding outward in what is
usually deemed an uncontrolled or exaggerated manner.201 Differences are also
observed at the terminal points of these disease pathologies. While AAA leads
to progressive outward remodeling and eventual erosion and rupture to the
outside of the vessel, atherosclerotic disease leads to inward occlusion of
vessels via plaque ruptures and subsequent thrombolytic responses. These
effects are not only disease dependent, but also appear to be location
dependent. For instance, the formation of AAAs are most common in the aortic
and cerebral vessels, but very rarely develop in the carotid, coronary, or femoral
arteries, which are the most common sites for atherosclerosis development.202-204
A consistent similarity in these disease processes is macrophage
accumulation in the development of both atherosclerotic and AAA pathology.
However, the mechanism of recruitment differs between these two diseases, as
is shown with intimal accumulation of macrophages in atherosclerotic disease,
and medial layer accumulation of macrophages in AAAs prior to dissection and
accumulation in adventitial layers.177,178 This difference may be associated with
the response to injury hypothesis in atherosclerotic prone areas, leading to lipid
accumulation, and subsequent infiltration of macrophages to engulf said lipid,
while AAAs are not initiated in this manner.205-207 However, the exact reason for
this difference is not known.
Numerous animal studies have also demonstrated differences in these
two AngII-induced vascular diseases. For example, administration of the broad
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spectrum matrix metalloproteinase (MMP) inhibitor doxycycline significantly
reduces the formation of AAAs, but demonstrates no effect on the formation of
atherosclerosis.208 Another pivotal experiment involving AT1a receptor deficiency
on bone marrow-derived cells demonstrated a modest reduction in AngII-induced
atherosclerosis, but no effect on AAA formation.41 Further experiments also
demonstrated orchidectomizing male hyperlipidemic mice led to profound
reductions in AngII-induced AAA and resultant increases in atherosclerosis
versus sham controls.148 These studies provide an experimental basis for
separation of atherosclerosis and aneurysm disease phenotypes. However, one
consistent theme demonstrated repeatedly is the involvement and necessity of
innate immune processes for both initiation and progression of atherosclerotic
and AAA disease processes.
Overview of Innate Immune Responses

General innate immune response
Innate immune cells represent the first line of defense against an invading
microorganism or circulating antigen. The main effectors of this arm of immunity
are of the phagocytic lineage, including monocyte/macrophages, dendritic cells,
and neutrophils. However, granular and leukocytic natural killer cells (NK cells),
mast cells, basophils, and eosinophils are also innate effectors. Pathogens
contain antigens not normally found in host tissues. The innate immune cells
recognize these antigens via pathogen-associated molecular patterns (PAMPs),
which subsequently lead to inflammatory responses, unlike adaptive immune B
and T lymphocytes, which are usually specific for a single antigen. Pattern
recognition receptors (PRRs) then recognize these PAMPS, are subsequently
activated, and rapidly signal through NF-6B and Map kinase pathways, leading to
up regulation of gene products.209-211 These products elicit paracrine and
autocrine cytokine and chemokine signals leading to mobilization of the other
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members of the innate immune system in a matter of minutes to hours.209-212
The majority of the PRRs relevant to vascular pathology are the
scavenger receptors (SR) and Toll-like receptors (TLRs). The most commonly
recognized PAMP is lipopolysaccharide (LPS), which is recognized by SR-A and
TLR4.209-211,213 Subsequent recognition of ligands leads to ligation of these
receptors. However, it is important to note that SR ligation leads to endocytosis
and eventual lysosomal degradation of the recognized antigen, while TLR
recognition leads to signaling via transmembrane pathways. Therefore, the
remainder of this section will examine the TLR pathway, which, when activated,
demonstrates augmented vascular disease processes.
Pattern Recognition Receptors (PRRs)
The most commonly associated PRRs with vascular disease and
inflammatory processes are the toll-like receptors (TLRs). The TLRs are
classified as Type I transmembrane proteins containing unique extracellular
leucine rich repeats (LRR) as well as a conserved intracellular Toll-interleukin-1
receptor (TIR) domain.214,215 The LRR domains are highly conserved, however,
they can recognize unique ligands that share no structural similarity.212,216 The
conserved TIR domain serves as a scaffold for signaling and is present in all
TLRs.217 To date, there have been 11 members of the toll family discovered in
mammals, including the interleukin 1 (IL-1) and IL-18 cytokine receptors, which
share the conserved TIR domain.217,218 Signaling for the TIR based TLRs is via
the MyD88 pathway, resulting in NF-6B, map kinase (MAPK), and AP-1
activation, resulting in increased inflammatory responsiveness.219 A MyD88independent pathway exists for TLR3 and 4, in which signaling is through
interferon responsive elements, leading to the activation of type I interferons "
and $.220
The MyD88 signaling subunit and its receptor complexes are expressed in
a variety of cell types including: SMCs,221,222 endothelial cells,223,224 fibroblasts,225,
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B cells,226 dendritic cells,227 and monocyte-derived cells mainly consisting of
macrophages,223,228 and, to a lesser extend, mast cells,229 and neutrophils.230
Activation of TLRs, via endogenous or exogenous ligands, can enhance the
production of matrix metalloproteinase-2 (MMP-2) and MMP-9,231,232 monocyte
chemoattractive protein-1 (MCP-1), interleukin 1 (IL-1), IL-6, IL-12, and
interferons ( ", $, and (), all of which have been linked to both atherosclerosis
and aneurysm pathologies.233,234
TLRs in atherosclerosis and aneurysm
Atherosclerosis is attenuated in IL-1$,235 TLR2,147,236 TLR4,237 and IL-18238
deficient mice on a hyperlipidemic background. All of these receptor types are
dependent on the MyD88 pathway for function, however, TLR4 also has a
MyD88 independent pathway. Recent studies have also demonstrated that
MyD88 deficiency, in apoE-/- mice, significantly reduced atherosclerotic lesion
formation in both the aortic sinus, and the intimal surface of the aorta.146,237
Furthermore, there was a concomitant reduction in inflammatory cytokines (IL12p40 and IL-1$), chemoattractive cytokines (MCP-1 and MIPs), and lipid
accumulation in MyD88 deficient mice. These two independent studies also
demonstrate a 75-80% reduction in the amount of macrophages found in the
atherosclerotic lesions in the aortic sinus.146,237 Furthermore, the elicitation of
mouse peritoneal macrophages (MPMs), in MyD88 deficient mice, is reduced
45% when compared to wild-type.146 These results show MyD88-/- mice secrete
less cytokines and chemokines, and have a possible defect in macrophage
function. Furthermore, these results suggest that the deficiency of innate
immune pathways in macrophages function can attenuate atherosclerotic
disease, similar to the osteopetrotic (op) mouse studies, which are monocytedepleted.239,240 A paucity of data exists with regard to the toll system in the
pathogenesis of AAA. The only existing report linking TLRs and AAAs is a gene
array of human aneurysm tissues showing up regulation of TLR1, TLR2, TLR6,
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TLR7, TLR8, MyD88, and CD14 mRNA levels compared to control tissues.241
This study also highlights an enormous role for immunity in the development of
AAA. Recently, the TLR pathway in the progression of AAA formation has
recently been described by our laboratory, showing that MyD88 and TLR4
deficiency significantly attenuate the formation of this disease (Chapter 5).
Translational studies, involving TLR4, also exist in the medical literature.
TLR4 is highly expressed in atherosclerotic lesions, colocalized to
macrophages.223 Furthermore, twelve polymorphisms have been discovered in
the human TLR4 receptor.242 Two common missense mutations are D299G and
T399I. The T399I is associated with only a mild disruption of signaling. The
D299G mutation is the most biologically relevant and has been linked to
lipopolysaccharide hyporesponsiveness, causing an ablation of TLR4 signaling
and cytokine production.243 The Bruneck clinical study suggests the D299G
polymorphism is associated with a decreased: intimal-medial carotid thickness,
carotid atherosclerosis, and inflammatory plasma markers IL-6 and C-reactive
protein.244 These findings were further confirmed by Ameziane et al., which
demonstrated patients with D299G polymorphisms had significant decreases in
fibrinogen and vascular adhesion molecule 1, which are both linked to
atherosclerosis.245 However, many conflicting studies have also been reported,
suggesting no changes in atherosclerosis progression over time.246,247 These data
suggest more analysis of the TLR pathway needs to be performed before a
definitive statement can be made on their role in human disease.
Associations of Innate Immunity in AngII-induced Vascular Disease
Macrophages are the most abundant inflammatory cells accumulating in
the subendothelial space in experimental atherosclerotic lesions. Op mice, that
lack macrophage colony stimulating factor (M-CSF), are monocyte-depleted and
have markedly reduced atherosclerotic lesions in either apoE-/- or LDL receptor/- backgrounds, with long-term fat feeding, suggesting a crucial role in the
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development of disease pathology.239,240 Recent studies have also demonstrated
AngII-induced atherosclerosis is also reduced, similar to the previously described
studies, in an apoE-/- background.174 However, the apoE-/- littermates, that were
wild type for M-CSF, failed to develop a significant number of AAAs. This result
was confounded by the background strain of the mice, which is resistant to AAA
formation. Also, op mice have many defects leading to difficulties in generating
these mice and may also engender interpretive difficulties. The contribution of
macrophages in the formation of AAA remains to be elucidated.
Recently, our laboratory has attempted to answer this question of
macrophage involvement in AAA pathology using the MyD88 deficient mouse
model, which has been attributed to demonstrate macrophage dysfunction.146
Our results demonstrate the deficiency of MyD88 has a profound reduction in
both atherosclerosis and AAAs (Figures 5.4 and 5.5). This effect was attributed
to signaling through the innate immune receptor, TLR4 (Figure 5.7).
Furthermore, up regulation of macrophages via high fat diet and AngII infusion is
significantly attenuated in these studies (Figure 5.8). We also demonstrate this
effect is due to bone marrow-derived cells expressing the MyD88 protein (Figure
5.9). These results indicate that the innate immune effector MyD88, as well as
the involvement of macrophages, is critical toward the formation of AngII-induced
atherosclerosis and AAA pathology.
Recent reports have also elucidated a role for mast cells in the
pathogenesis of atherosclerosis and AAA.248,249 Mast cells represent another
innate immune mediator, that induce a proinflammatory profile usually associated
with immediate hypersensitivity and chronic allergenic reactions. These studies
show mast cell-deficient KitW-sh/kitW-sh mice are important participants in the
pathogenesis of both atherosclerosis and AAA. Furthermore, they demonstrate
mast cell-specific upregulations of IL-6 and IFN-( cytokines are responsible for
this effect using bone marrow-derived mast cell populations from mice deficient
in the aforementioned cytokines.248,249 These studies were not conducted using
the AngII model of vascular disease, but instead fat fed-induced atherosclerosis
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and the calcium chloride and elastase model of AAA formation.250-252 While
similarities exist in diet-induced and AngII-induced atherosclerosis; the elastase
and calcium chloride models are not similar in that they mainly result in
adventitial thickening and not true aneurysm formation, in regard to lumenal
expansion (as shown in figure 2B Sun et al.).248,249 Nonetheless, these studies
demonstrate a mechanism for mast cell deficiency to decrease vascular disease.
The neutrophil, which is the earliest innate-mediator cell to arrive at sites
of inflammation and injury, has been demonstrated to mediate the formation of
AAA in the elastase model. Studies using elastase-induced AAAs in rats
demonstrated L-selectin up regulation and the association of said up regulation
with macrophage and neutrophils.253 These studies were confirmed in L-selectin
ablated mice, resulting in less macrophage and neutrophil accumulation and
significantly attenuated AAA formation.253 This L-selectin ablation study was also
confirmed with neutropenia induced using anti-PMN antibody injections resulting
in significant attenuation of AAA size and incidence.254 However, the L-selectin
and neutropenia studies also have a concomitant down regulation in
macrophages, and therefore it is not clear whether the actions are being
mediated by neutrophils or macrophages. This will require subsequent
investigations to separate out the two cell types. While neutrophils are most
certainly present in atherosclerotic disease, studies involving neutrophil depletion
have yet been examined. Interestingly, a study involving the deficiency of
myeloperoxidase (MPO) demonstrated an increase in atherosclerotic lesions in
fat-fed animals.255 MPO is a heme enzyme produced and secreted by activated
phagocytic cells, which upregulates a host of oxidative processes. More
importantly, MPO makes up 5% of neutrophil protein and is considered the main
weapon in the neutrophil’s arsenal.256 Therefore, this study begs the question
whether the neutrophil is a friend or a foe in atherosclerosis.
NK cells also perform a substantial role in the pathogenesis of vascular
disease. Transgenic mice with overexpression of the inhibitory major
histocompatability complex (MHC) class I-specific receptor, Ly49A, prevent the
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activation of NK cells, and thus these mice have the absence of functional NK
cells.257 Recent bone marrow transplantation studies with these Ly49A mice, in
an AngII-infusion model of atherosclerosis, demonstrated a 70% reduction in the
size of aortic sinus lesions and a 38% reduction in en face analysis of the aortic
arch.258 However, these results are complicated by conflicting studies using lystbeige mutant mice, which also demonstrate decreased NK cell function.132,133,140
These beige mice demonstrate either no change in mice fed a atherogenic
‘paigen’ diet,156 or minimally, but significantly, upregulated atherosclerosis in an
LDL receptor-/- model.259 The analysis in this lyst-beige model are complicated
by phenotypic abnormalities, such as defects in macrophages and T/B
lymphocytes, and further, do not have a complete defect in NK cells.132,133,140
This, therefore, questions the validity of the lyst-beige studies in regard to
specificity to NK cells, when compared to specific knock down of NK cells, as is
shown in the Ly46 studies. A more recent study crossed the beige mutant mice
into an apoE-/- background and found a reduction in chow-fed atherosclerosis
and an increase in diet-induced atherosclerosis dependent on both resident and
marrow cells.160 These results demonstrate a complex phenotype in these beige
mutants. Currently, the role of NK cells in AngII-induced AAAs has not yet been
elucidated.
Summary
AngII administration to hyperlipidemic mice results in the reproduceable
vascular pathology of atherosclerosis and AAAs. These vascular disease
processes differ in their progression, however, are similar in initiation involving
key mediators of the innate immune system. To date, studies have ascertained a
role for macrophages, mast cells, and NK cells in atherosclerosis, while
macrophages, mast cells, and neutrophils have been examined in AAAs.
However, it is not currently understood how depletion of one cell type leads to
reductions/enhancements in pathology that is not compensated by another cell
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type. This is an ongoing quandry of these cumulative examinations of genetic
ablation studies. To conclude, innate immunity demonstrates a critical role in
initiation of atherosclerosis and AAA pathogenesis.

Copyright © Albert Phillip Owens III 2008
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Chapter Five: Angiotensin II and Region-specific Vascular Disease: Toll-like
Receptor 4 Attenuates Angiotensin II-induced Atherosclerosis and
Suprarenal Abdominal Aortic Aneurysms via a Myeloid Differentiation
Factor 88-dependent Mechanism.

5.1

Synopsis:

Angiotensin II (AngII) infusion augments atherosclerosis and induces abdominal
aortic aneurysms (AAAs), which are both characterized by macrophage
infiltration. This study ascertained the effects of MyD88 deficiency on AngIIinduced vascular pathologies and the toll receptor (TLR) responsible for this
effect. AngII incubation of primary cultures upregulated TLR2, TLR4, CD14, and
MyD88 mRNAs. Further, AngII-induced atherosclerotic lesions and AAAs stain
positive for TLR4 and MyD88. Male mice with or without deficiency in MyD88,
TLR2, and TLR4, on a low density lipoprotein receptor (LDLr) deficient
background, were fed a fat-enriched diet and infused with AngII (1,000ng/kg/min)
for 28 days. Deficiency of MyD88, TLR2, or TLR4 attenuated AngII-induced
augmentation of atherosclerosis. However, only MyD88 and TLR4 deficiency
attenuated diameter of the suprarenal abdominal aorta and AAA formation. To
determine the cell type responsible for this effect, bone marrow transplantation
studies were performed. LDLr-/- male mice were irradiated and repopulated with
bone marrow from MyD88 (+/+ vs. -/-) or TLR4 (+/+ vs. -/-) mice, respectively.
Repopulation of MyD88+/+ animals with deficient bone marrow-derived cells
similarly reduced AngII-induced vascular pathology to whole body ablation.
However, TLR4+/+ repopulation with -/- bone marrow-derived cells did not show
a change in AngII-induced vascular disease. The present study defines an
important link between AngII-induced vascular pathology and innate immunity
and suggests alternate mechanisms for initiation and progression of disease.
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5.2

Introduction:
Angiotensin II (AngII) infusion into hyperlipidemic mice enhances

atherosclerosis and induces abdominal aortic aneurysms (AAAs).139,181 Although
AngII promotes both vascular diseases, their pathologies imply they are
generated via different mechanisms. Pharmacological, surgical, and genetic
manipulations can have differential effects on the severity of these diseases. A
major difference is the intimal macrophage accumulation throughout the
development of AngII-induced atherosclerosis, while macrophage accumulation
in the media of the aorta and progression to the adventitia is the characteristic of
the initial to the late stages, respectively, of AngII-induced AAA
development.139,177
Macrophages are the most abundant cells in experimental atherosclerotic
lesions. The functional role of this cell type in the development of lesions has
been demonstrated in monocyte-depleted mice. Osteopetrotic (op) mice, that
lack macrophage colony stimulating factor (M-CSF), have reduced circulating
monocytes and markedly reduced atherosclerotic lesions on either apolipoprotein
E deficient (apoE-/-) or LDLr-/- backgrounds.239,240 Macrophages are present
throughout the initiation and maturation stages of AngII-induced AAA formation,
although their functional role has not been defined in this disease.177 Previously
published results used apoE-/- op mice to study the contribution of macrophages
to AAA formation.174 However, the apoE-/- littermates, that were op+/+ for MCSF, failed to develop a significant number of AAAs. This may have been
attributable to the mixed strain background of the op mice, which differs from the
C57BL/6 background used for all other studies. Thus, the contribution of
macrophages to AAA formation has not been determined using mice with
macrophage depletion.
Recently, a considerable attention has been drawn in myeloid
differentiation factor 88 (MyD88) as a major regulator in the innate immune
signaling pathways. This mediator protein is the signaling component for the toll80

like receptors (TLRs).211,212 Numerous studies have demonstrated that MyD88
deficiency, as well as TLR1, TLR2, TLR4, and IL-18 deficiency, decreases the
size of atherosclerotic lesions.146,147,235-238 MyD88 deficiency produces multiple
defects in macrophage functions.146,237 However, MyD88 is expressed in all cells
involved in vascular pathology and the contribution of macrophage specific
deficiency to lesion formation has not been determined.
The aim of the present study was to determine whether MyD88 deficiency
in a hyperlipidemic background provides a model for determining the role of
functionally deficient macrophages on AngII-induced atherosclerosis and AAA
formation. MyD88 deficiency on either an apoE-/- or LDLr-/- background resulted
in a profound reduction in AngII-induced atherosclerosis and AAA formation.
Further, this effect was dependent upon bone marrow-derived cells. TLR2 and
TLR4 deficiency were examined as receptor mediators of this MyD88 effect.
Both receptors significantly attenuated atherosclerosis formation, however, only
TLR4 deficiency resulted in ablation of AAA formation.
5.3

Materials and Methods:

Experimental animals and diet
Male apoE-/- mice (originating from the Jackson Laboratory) that were
MyD88+/+ (n=42) and -/- (n=28) were a kind gift of Mason Freeman and Kathryn
Moore (Harvard U).146 These mice were 8x backcrossed on a C57BL/6
background and additionally crossed into apoE-/- background (10x) for a total of
9x backcrossing into C57 background. Additionally, the MyD88 mice were bred
out of an apoE-/- background and into a LDLr-/- (+/+: 19; -/-: 23) background
(originating from the Jackson Laboratory) resulting in a full 10x backcrossing into
the C57BL/6. Additionally, TLR2+/+ (n=9), TLR2-/- (n=11), TLR4+/+ (n=14) and
TLR4-/- (n=20) mice in an LDLr-/- background and backcrossed 10x C57BL/6
were a kind gift of Linda Curtiss (Scripps Inst.), Peter Tobias (Scripps Inst.), and
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Shizuo Akira (Osaka U).147 These mice were all bred as littermate controls, and
were housed in a pathogen-free barrier facility. All MyD88 mice were given
sterile autoclaved antibiotic water (Sulfatrim 0.2%) ad libitum, while the TLR2 and
TLR4 mice were given normal reverse osmosis water ad libitum. All apoE-/mice were fed a normal mouse laboratory diet throughout experimentation.
LDLr-/- animals were fed a normal laboratory diet, until induction of
hypercholesterolemia, when the diet was supplemented with saturated fat (milk
fat 21% wt/wt) and cholesterol (0.15% wt/wt, diet number TD88137; Harlan
Teklad). All studies were performed with the written approval of the University of
Kentucky Institutional Animal Care and Use Committee (IACUC).
Osmotic minipump implantation
At 8 to 12 weeks of age, mice were implanted with Alzet osmotic
minipumps (model 2004, Durect Corporation), subcutaneously into the right flank,
and infused with AnII (1,000 ng/kg/min, Bachem) for a period of 28 days, as
described previously.177
Genotyping by polymerase chain reaction
MyD88 genotyping used the following primers: MyD88 forward
5'–TGGCATGCCTCCATCATAGTTAACC–3', MyD88 reverse
5'–GTCAGAAACAACCACCACCATGC–3', and MyD88 neo
5'–ATCGCCTTCTATCGCCTTCTTGACG–3'. All primers were combined into
one solution and the resultant wild-type and deficient allele bands were 550 and
600 basepairs (bp), respectively. TLR4 genotyping used the following primers:
HC-26 forward 5'–TGTTGCCCTTCAGTCACAGAGACTCTG–3', HC-27 reverse
5'–CGTGTAAACCAGCCAGGTTTTGAAGGC–3', and HC-28 neo
5'–ATCGCCTTCTATCGCCTTCTTGACGAG–3'. HC-26 and 27 were combined
in one reaction for wild-type allele bands at 1300 bp, while HC-26 and 28 were
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combined in another reaction for deficient allele bands at 1300 bp. TLR2
genotyping used the following primers: HC-23 forward
5'–TTGGATAAGTCTGATAGCCTTGCCTCC–3', HC-24 reverse
5'–GTTTAGTGCCTGTATCCAGTCAGTGCG–3', and HC-25 neo
5'–ATCGCCTTCTATCGCCTTCTTGACGAG–3'. HC-23 and 24 were combined
in one reaction for wild-type allele bands at 900 bp, while HC-23 and 25 were
combined in another reaction for deficient allele bands at 900 bp. All mice were
genotyped and this screen was verified by two people. All bone marrow
experiments had femurs genotyped at time of euthanasia to verify successful
repopulation of recipient cells.
Aortic tissue and plasma collection
Twenty-eight days after pump implantation, mice were sedated with a
mixture of ketamine and xylazine. Blood was drawn into a 23 gauge needle
containing 0.2% EDTA from the left ventricle of the heart and immediately
centrifuged 2,000 rpm for 20 minutes to collect plasma. Mice were then
euthanized via ligation of the right atrial septum. Aortas were perfused with
sterile saline and subsequently extracted from the mouse and placed into 10%
formalin overnight. These aortas were then carefully cleaned free of all
extraneous adventitia and stored until photography and atherosclerosis analysis.
Quantification of atherosclerosis
Atherosclerosis was quantified using en-face analysis, or the cutting of the
aortic root down to the aortic aspect, in order to visualize lesions on the intimal
surface of the aorta from the aortic arch to the upper thorax (approximately 3mm
posterior to aortic aspect).238 Thoracic en face atherosclerosis was quantitated in
a similar manner (3mm posterior to aortic aspect to last intercostal artery).
Lesions on the intimal surface and aortic arch and thoracic area were traced
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using Image-pro software. Atherosclerosis is represented as the sum of the
lesion areas divided by the area of the vessel for each region.
Abdominal aortic measurements
Abdominal aortas were pinned on wax and multiple magnified
photographs were taken of the arch, thoracic, and abdominal regions using a
millimeter ruler as a calibrator. Maximum width of abdominal aortas were
measured using computerized morphometry (Image-Pro Software, ). Suprarenal
abdominal diameter was quantified using external diameters to classify incidence
of AAA (defined as a dilation greater than 50% of the normal vessel diameter of
0.80mm).198
Ultrasound Imaging
High resolution ultrasound was performed on all animal subjects prior to
pump implantation and on day 28 of infusion. This measurement was used to
confirm external abdominal aortic measurements were based on lumenal
dilatation and not adventitial thickening. Two-dimensional imaging using realtime microvisualization was performed using a Visualsonics Vevo 770, as
previously described.198
Irradiation and bone marrow repopulation
Mice were provided antibiotic water (Sulfratrim 0.2%) one week prior to
irradiation. Recipient LDLr-/- mice (TLR4+/+: n=23; MyD88+/+: n=22) were
irradiated with two separate doses of 450 Rads from a cesium source, delivered
4 hours apart. Bone marrow-derived cells from MyD88+/+ or -/- x LDLr-/- and
TLR4+/+ or -/- x LDLr-/- donor mice were obtained from the femurs and then
subsequently injected into the tail vein of 7-8 week old irradiated recipient mice
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(1x107 cells per animal). These recipient mice were maintained on antibiotic
water for the next four weeks, and were then returned to normal reverse
osmosis water before beginning experimentation.41
White blood cell analysis
White cell counts in whole blood were immediately sampled, at time of
collection, on a Hemavet 950 LV veterinary multi-species hematology system
(Drew Scientific, Waterbury, CT).
Blood monocyte determination with flow cytometry
MyD88-/- x LDLr-/-, TLR4-/- x LDLr-/-, and LDLr-/- mice were either fed
high fat diet for 1 month (n=5 each) or fed a fat enriched diet for 3 weeks with 2
weeks AngII infusion (n=5 each). Peripheral blood monocyte populations were
determined via fluorescence-activated-cell sorter (FACS) using fluorescently
labeled antibodies against CD115 (phycoerythrin, eBioscience catalog 12-116283), F4/80 (biotinylated, Serotec catalog MCA497B), or Gr-1 (PerCp-Cy5.5, BD
Pharmingen catalog 552093). The biotinylated antibody was detected using
secondary streptavidin-APC (eBioscience). Briefly, blood was collected, as
previously described above, and 200:l of whole blood was placed into
Szilvassey’s red blood cell (RBC) lysis solution. RBC lysis solution was
quenched with BSA-rich Hank’s buffered saline solution (HBSS). FACS staining
buffer was composed of 5ml 1x phosphate buffered saline, and 5ml HBSS, with
the addition of 333:l 30% BSA and 100:l normal rabbit and normal mouse
serum. Primary antibodies were incubated 1:200 for 30-40 minutes on ice,
washed, and then placed in 1:400 secondary antibody. Double positive CD115
and F4/80 monocyte populations were classified as Ly-6C low, intermediate, and
high, as described previously.260 Staining protocols were generously provided by
Dr. Gwendalyn Randolph (Mt. Sinai, NY).260
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Thioglycollate elicitation of peritoneal macrophages
MyD88-/- (n=10), TLR4-/- (n=5), and LDLr-/- (n=10) mice were fed a high
fat western diet for one week. These mice were then injected with 1ml 3%
thioglycollate media resuspended in sterile saline. After 4 days of incubation,
mice were sedated and subsequently cleared of all blood. The abdominal region
was cleaned with 75% ethanol, cleared of all fur, and peritoneal macrophages
were extracted using 5ml sterile saline via an 18 gauge needle.261 Cells were
incubated with RBC lysis solution and then centrifuged 1,000 rpm for 5 minutes.
Cells were resuspended in 200:l of sterile saline, of which 20:l was used for
white blood cell calculations, while 1:l was diluted 1:20 and counted on a
hemacytometer. The remaining solution was stained with fluorescently labeled
CD68-FITC (Serotec, MCA1957F) 1:10 and analyzed via FACS for percent
macrophages in the peritoneum.
Measurement of plasma lipids
Plasma cholesterol concentrations were analyzed using a commercially
available Cholesterol E enzymatic kit (Wako Chemical Company, Richmond, VA).
Lipoprotein cholesterol distribution was performed by fast protein liquid
chromatography (FPLC), which separates lipoprotein fractions by size exclusion,
on a double superose 6 column. Collected fractions were assayed with the
Cholesterol E enzymatic kit (Wako).139
Blood pressure measurements
Systolic blood pressure (SBP) was measured noninvasively in tail arteries
of conscious mice using the Coda 8 Kent blood pressure system (Kent Scientific
Corp, Torrington, Connecticut). Mice were measured 5 days prior to pump
implantation, and during the last 5 days of drug administration.190
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Immunohistochemistry
Frozen atherosclerotic and AAA sections were fixed in 4%
paraformaldehyde for 10 minutes. Sections were stained for macrophages
(Accurate Chemical), MyD88 (Abcam), and TLR4 (Santa Cruz). Tissue sections
were blocked with nonimmune rabbit serum. Immunohistochemical analysis was
conducted using a Microprobe system (Fisher Scientific) and Vectastain Elite
ABC kit (Vector). Negative controls were no primary, no primary no secondary,
and isotype-matched irrelevant antibodies. Immunoreactivity was visualized by
using 3-amino 9-ethyl carbazole (Biomeda Corp), which is visualized by a red
precipitate. Tissue sections were then counterstained with aqueous hematoxylin
(Biomeda).177
Real-time polymerase chain reaction
Vascular smooth muscle cells and thioglycollate-elicited mouse peritoneal
macrophages were harvested from C57BL/6 mice and plated. These cells were
treated with saline (24 hours), AngII (1:M, bachem, 24 hours),
lipopolysaccharide (1:g/ml, TLR4 agonist, invivogen, 3 hours), and Pam3CSK4
(1:g/ml, TLR2 agonist, invivogen, 3 hours). Samples were washed and then
RNA was harvested using the Qiagen All Prep RNA/protein kit. All samples were
incubated with Turbo DNA-free (Ambion, cat# AM1907) to remove all DNA
contamination. RNA concentrations were quantified using a UV
spectrophotometer (Beckman DU530). Reverse transcription of RNA was
performed using i-script (Bio-Rad, cat# 170-8891) with a concentration of 100 ng
total RNA. Real-time analysis of the cDNA was performed using a Bio-Rad icycler with TLR2 (Applied Biosystems (AB) catalog Mm01213946_g1), TLR4 (AB
catalog Mm00445273_m1), MyD88 (AB catalog Mm00440339_g1), and CD14
(AB catalog Mm00438094_g1) taqman probes and IQ supermix (Bio-Rad, cat#
170-8860). These results were compared to an 18s rRNA endogenous control
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(Applied Biosystems, cat# 4352930E). Results were extrapolated using the delta
Ct method. Negative controls consisted of no RT controls.
Statistics
All statistical analyses were performed using either SigmaStat (SPSS Inc.)
or version 8.2 of SAS (SAS Institute, Cary, NC). All measurements are
represented as the mean ± S.E.M. One Way ANOVA was performed on
measurements, where indicated, with a Holm-Sidak post hoc test. A Student’s ttest was performed on the nuclei counts. Repeated measures data was
analyzed with SAS fitting a linear mixed model expressing the temporal trend in
systolic blood pressure as a quadratic polynomial in time for each treatment. A
Bonferroni-adjusted pairwise comparison was performed within similar genotypes
among treatments.
5.4

Results:

AngII augments innate immune Toll pathway components in vitro and in
vivo
Numerous studies have associated innate immunity with AngII-induced
pathologies, however, a paucity of data exists connecting this pathology to the
toll pathway. Therefore, we first examined whether AngII mediates components
of the toll pathway in vitro with direct treatment of primary cell cultures or in vivo
via vascular pathology models. Elicited peritoneal macrophages (Figure 5.1a) or
VSMCs (Figure 5.1b) treatment with AngII significantly increased the mRNA
expression levels of TLR2, TLR4, and the adaptor molecule CD14 similar to a
TLR2 (Pam3CSK4) or TLR4 (LPS) agonist. MyD88 was upregulated in cultured
macrophages, but unchanged in cultured VSMCs.
To provide a basis for these molecules in AngII-induced vascular
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pathologies, immunostaining was performed on atherosclerotic lesions and AAA
tissues. Both MyD88 and TLR4 were present in AngII-induced atherosclerotic
lesions (Figure 5.2) and AAA tissues (Figure 5.3) colocalized with macrophages.
Therefore, AngII can upregulate Toll pathway components, and these proteins
are present in AngII-induced vascular pathologies.
Deficiency of MyD88 prevents AngII-induced atherosclerosis and AAAs
MyD88 deficiency abolishes signaling of all toll receptors, with the
exception of the TLR4 and TLR3 MyD88-independent signaling pathways. To
determine the contribution of MyD88 to AngII-induced atherosclerosis and AAA
pathology, MyD88+/+ and -/- mice, on an apoE-/- background, were infused with
AngII (1000 ng/kg/min) for 28 days. Since many pro-inflammatory effects are
mediated by deficiency of apoE,262 MyD88+/+ and -/- mice were also examined
on an LDLr-/- background and fed a high fat-enriched diet. Deficiency of MyD88,
on either an apoE-/- or LDLr-/- background, had no effect on plasma cholesterols
or SBP (pre and post infusion, Table 5.1). No difference was detected between
MyD88 genotypes, on the apoE-/- background, with regard to body weight.
However, after fed a fat-enriched diet for 5 weeks, MyD88-/- mice had a 13%
increase in body weight (Table 5.1).
AngII-induced atherosclerosis was quantified on the intimal surface of the
aortic arch and thoracic aorta. MyD88 deficiency ablated atherosclerosis in both
aortic regions on the apoE-/- (arch: 82.3%; thorax: 79.1% decrease) and the
LDLr-/- (arch: 64%; thoracic: 87% decrease) backgrounds (Figures 5.4a and
5.5a).
Infusion of AngII into MyD88+/+ mice led to a significant increase of
suprarenal aortic diameters (apoE-/-: 1.5 ± 0.17mm; LDLr-/-: 2.0 ± 0.2mm;
Figures 5.4b and 5.5b, P<0.001), while MyD88 deficiency attenuated abdominal
aortic expansion (apoE-/-: 0.97 ± 0.08mm; LDLr-/-: 0.99 ± 0.04mm).
Furthermore, MyD88 deficiency also significantly attenuated arch aneurysm and
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area, AAAs, and rupture-induced death versus proficient animals (Table 5.2,
P<.001).
TLR2 and TLR4 attenuate AngII-induced atherosclerosis, while only TLR4
mediates AngII-induced AAAs
To establish the toll receptor mediating the MyD88 effects, TLR2 receptor
deficiency was examined. TLR2+/+ and -/- mice, on an LDLr-/- background,
were fed a high fat-enriched diet for 5 weeks and infused with AngII (1000
ng/kg/min) for 28 days. No differences were detected in plasma cholesterol
levels, body weight, or SBP (Table 5.1). Atherosclerotic lesions in both aortic
arch (73% decrease) and thoracic aorta (87% decrease) were attenuated in
TLR2-/- mice (Figure 6a, P<0.001). However, TLR2 deficiency did not alter
AngII-induced increases in suprarenal aortic diameters (+/+: 2.0 ± 0.22mm; -/-:
1.8 ± 0.2mm, Figure 5.6b), aortic arch area or aneurysm (+/+: 44%; -/-: 36%),
AAAs (+/+: 89%; -/-: 82%), or rupture-induced death (+/+: 22%; -/-: 36%, Table
2). This demonstrates MyD88 mediated aneurysmal formation is not through the
TLR2-MyD88 axis.
It has been reported that TLR4 mediates vascular pathologies and signals
through the MyD88 pathway.237 Therefore, we also examined TLR4+/+ and -/mice, on an LDLr-/- background, in the development of atherosclerosis and
AngII-induced aneurysm formation. TLR4 genotypes had similar body weights
and plasma cholesterol levels. However, TLR4 deficiency significantly reduced
both pre and post infusion SBP levels by approximately 12mmHg (P<0.005).
Ablation of TLR4 significantly attenuated AngII-induced atherosclerosis in both
the aortic arch (55%) and thoracic aorta (66%, Figure 5.7a, P<0.001). Deficiency
of TLR4 also significantly decreased suprarenal aortic diameters (+/+: 2.23 ±
0.37mm; -/-: 1.03 ± 0.05mm, Figure 5.7b, P<0.001), AAAs (+/+: 64%; -/-: 25%)
and abdominal aortic aneurysm (+/+: 100%; -/-: 25%, Table 5.2, P<.01).
However, TLR4 deficiency had no effect on rupture-induced death or aortic arch
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area. These data are consistent with TLR4 being the major receptor for MyD88induced effects on AngII-induced aneurysmal formation.
MyD88 deficiency results in dysfunctional monocyte/macrophage
populations.
AngII infusion significantly increased white blood cells, neutrophils, and
monocytes (Figure 5.8a, P<0.001). However, while MyD88+/+ and -/- resulted in
similar levels of WBCs prior to AngII infusion, WBCs in deficient mice remained
unchanged after 28 days of infusion.
Blood monocyte populations were examined in male MyD88-/- x LDLr-/-,
TLR4-/- x LDLr-/-, and LDLr-/- mice. TLR4-/- and LDLr-/- mice had an increase
of 447% and 390%, respectively, after 28 days of fat feeding, while deficiency of
MyD88 only increased blood monocyte levels 82% (Figure 5.8b, P<.001).
Moreover, MyD88 deficiency elicited 62% fewer CD68+ macrophages than LDLr/- mice (Figure 5.8c, P<.001). This data is consistent with MyD88 deficiency
having defective regulation of monocyte/macrophage populations.
The aforementioned monocytes were further categorized into 3
subpopulations of Ly-6C (Ly-6Clow, Ly-6Cint, and Ly-6Chi), which are associated
with distinct chemokine receptor profiles.260 MyD88 deficiency significantly
increased Ly-6Clow and decreased Ly-6Chi monocyte populations with 4 weeks of
high fat diet versus TLR4-/- and LDLr-/- mice (Figure 5.9a, P<.007) Further, AngII
infusion significantly increased the inflammatory profile of monocytes in LDLr-/mice, while MyD88 deficiency remained unchanged when compared to saline
(Figure 5.9b). TLR4 deficiency augmented Ly-6Chi monocyte populations,
independent of treatment.
MyD88 donor genotype is the major determinant of vascular diseases in
chimeric mice infused with AngII, independent of TLR4 signaling
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Upon the demonstration of a critical role for MyD88 and TLR4 in the
development of AngII-induced vascular pathologies and the general impairment
of monocytes in peripheral blood of MyD88-/- mice, we used bone marrow
transplantation to define the involvement of hematopoeitic cells. First, male
MyD88+/+ x LDLr-/- mice were irradiated and subsequently repopulated with
bone marrow-derived cells from MyD88+/+ or -/- animals. Genotype was verified
from femur-derived bone marrow at time of sacrifice (unpublished).
Recipients of MyD88+/+ or -/- bone marrow had no change in body
weights, plasma cholesterols, blood pressures, or WBCs (Table 3). Intimal
atherosclerotic lesions were significantly attenuated in both aortic arch (35%) and
thoracic aorta (77%, Figure 5.10a, P<.006) in MyD88+/+ mice repopulated with
MyD88-/- donor cells, compared to those repopulated with MyD88+/+ bone
marrow-derived cells. Similar to the results of whole body deletion, deficiency of
MyD88 in bone marrow-derived cells significantly attenuated suprarenal aortic
width (repopulated with +/+ donor cells: 1.51 ± 0.12 mm; with -/- donor cells:
1.02 ± 0.07mm, Figure 5.10b, P<0.001). Infusion of AngII into MyD88+/+ mice
repopulated with MyD88+/+ bone marrow-derived cells resulted in a 68%
incidence of AAA versus only 9% (P<0.001) in those repopulated with MyD88-/bone marrow-derived cells. Furthermore, arch area (+/+ repopulation: 22.3 ±
0.81 mm; -/- repopulation: 18.9 ± 0.46 mm) and arch aneurysm (+/+ repopulation:
59%; -/- repopulation: 13%) was also significantly decreased when comparing
MyD88+/+ to MyD88-/- donors in recipient mice. No difference was found in
rupture-induced deaths (4% each donor genotype).
To determine whether this bone marrow cell-derived effect was mediated
by TLR4 in the same cell type, mice that were TLR4+/+ x LDLr-/- were irradiated
and repopulated with TLR4+/+ or -/- bone marrow-derived cells. Donor cell
repopulation was confirmed as described in the MyD88 study (unpublished).
Body weight, SBPs, plasma cholesterol, and white blood cells (except platelet
numbers, which were significantly lower in the recipient mice repopulated with
TLR4-/- bone marrow-derived cells) were unchanged between recipients (Table
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5.3). Intimal atherosclerotic lesions were unchanged between the TLR4+/+
recipients repopulated with TLR4+/+ and -/- donors (Figure 5.11a). Surprisingly,
the suprarenal diameter (+/+ donors: 1.4 ± 0.09mm; -/- donors: 1.52 ± 0.11mm)
and incidence of AngII-induced AAAs (+/+ donors: 55%; -/- donors: 48%) were
not significantly altered by repopulation with TLR4-/- bone marrow-derived cells
into +/+ recipients (Figure 5.10b). In addition, no differences were observed in
aortic arch area (+/+ donor: 21.9 ± 0.69 mm; -/- donor: 22.0 ± 0.80 mm) and
aneurysm incidence (+/+ donor: 50%; -/- donor: 43%) or rupture-induced death
(+/+ donor: 0%; -/- donor: 13%).
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Figure 5.1: AngII increases innate immune mRNA expression in vascular
and hematopoietic cells. MyD88, TLR2, TLR4, and CD14 real-time mRNA
expression levels in (A) thioglycollate-elicited mouse peritoneal macrophages
and (B) abdominal aortic smooth muscle cells treated with saline, AngII (1:M),
LPS (1:g/ml), or Pam3CSK4 (1:g/ml). Values were extrapolated using the delta
delta Ct method with saline treatment as control and 18s rRNA as the internal
control. Histobars represent the means of 6 samples and bars are represented
as SEM. *Denotes P<.004 in AngII, LPS, and Pam3CSK4 treatments versus
saline. #Denotes P<.002 in LPS and/or Pam3CSK4 treatments versus AngII.
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Figure 5.2: AngII-induced atherosclerotic lesions express MyD88 and TLR4
colocalized to macrophages. Atherosclerotic sinus sections from AngII infused
LDLr-/- mice were stained for control nonimmune rabbit serum (A), rabbit IgG, (C
and E), macrophage (B), MyD88 (D), or TLR4 (F). Positive staining was
represented by red coloration. Magnification = 200x.
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Figure 5.3: MyD88 and TLR4 colocalize with macrophage staining in AngIIinduced AAAs. AAA sections from AngII infused LDLr-/- mice were stained for
control nonimmune rabbit serum (A), rabbit IgG (C and E), accurate macrophage
(B), MyD88 (D), or TLR4 (F). Positive staining was represented by red
coloration. Magnification = 200x.
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Figure 5.4: MyD88 deficiency attenuates AngII-induced vascular pathology
in apoE-/- mice. (A) Atherosclerotic lesion area was measured on aortic arch
and thoracic intimal surfaces and taken as a percentage of total arch and
thoracic area, respectively. (B) Measurements of maximal external width of
abdominal aortas (mm). Clear circles (MyD88+/+) and gray circles (-/-) represent
individual mice, diamonds represent means, and bars are SEMs. *P<.001 MannWhitney Rank Sum analysis MyD88+/+ vs -/- arch and thoracic atherosclerosis.
#P<.001 Fisher’s Exact Test MyD88+/+ vs -/- abdominal aortic width.
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Figure 5.5: MyD88 deficiency attenuates AngII-induced vascular pathology
in LDLr-/- mice. (A) Atherosclerotic lesion area was measured on aortic arch
and thoracic intimal surfaces and taken as a percentage of total arch and
thoracic area. (B) Measurements of maximal external width of abdominal aortas
(mm). Clear circles (MyD88+/+) and gray circles (-/-) represent individual mice,
diamonds represent means, and bars are SEMs. *P<.001 Mann-Whitney Rank
Sum analysis MyD88+/+ vs -/- arch and thoracic atherosclerosis. #P<.001
Fisher’s Exact Test MyD88+/+ vs -/- abdominal aortic width.
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Figure 5.6: TLR2 deficiency attenuates AngII-induced atherosclerosis, but
did not change AAAs in LDLr-/- mice. (A) Atherosclerotic lesion area was
measured on aortic arch and thoracic intimal surfaces and taken as a percentage
of total arch and thoracic area. (B) Measurements of maximal external width of
abdominal aortas (mm). Clear circles (TLR2+/+) and gray circles (-/-) represent
individual mice, diamonds represent means, and bars are SEMs. *P<.001 MannWhitney Rank Sum analysis TLR2+/+ vs -/- arch and thoracic atherosclerosis.
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Figure 5.7: TLR4 deficiency attenuates AngII-induced vascular pathology
in LDLr-/- mice. (A) Atherosclerotic lesion area was measured on aortic arch
and thoracic intimal surfaces and taken as a percentage of total arch and
thoracic area. (B) Measurements of maximal external width of abdominal aortas
(mm). Clear circles (TLR4+/+) and gray circles (-/-) represent individual mice,
diamonds represent means, and bars are SEMs. *P<.001 Mann-Whitney Rank
Sum analysis TLR4+/+ vs -/- arch and thoracic atherosclerosis. #P<.001 Fisher’s
Exact Test TLR4+/+ vs -/- abdominal aortic width.
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Figure 5.8: AngII augmentation of WBCs, HFD-induced monocytes, and
elicitation of macrophages are attenuated by MyD88 deficiency. (A) AngII
infused MyD88+/+ (n=19) and -/- (n=23) mice (on high fat diet and LDLr-/background) whole blood examined on hemavet analyzer. (B) LDLr-/- (n=10),
MyD88-/- (n=10), and TLR4-/- (n=10) comparison of whole blood monocyte
double positive populations of CD115 (M-CSF receptor 1) and F4/80 before and
after 1 month high fat diet. (C) LDLr-/- (n=10), MyD88-/- (n=10), TLR4-/- (n=5)
thioglycollate elicited CD68+ peritoneal macrophages. Genotypes represented as
follows: LDLr-/- open bars, MyD88-/- hatched bars, TLR4-/- filled bars.
*Represents P<0.001 Mann-Whitney Rank Sum analysis MyD88-/- versus LDLr/- or TLR4-/-.
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Figure 5.9: MyD88 deficiency augments Ly-6Clow and attenuates Ly-6Chi
subpopulations of peripheral blood monocytes. (A) LDLr-/- (n=8), TLR4-/(n=7), and MyD88-/- (n=8) mice were fat fed for 1 month and peripheral blood
monocytes (CD115+ and F4/80+) were divided into Ly-6C low, intermediate, and
high subpopulations. Genotypes represented as follows: LDLr-/- open bars,
TLR4-/- hatched bars, MyD88-/- filled bars. *Represents P<0.001 One Way
ANOVA on ranks MyD88-/- versus LDLr-/- or TLR4-/- within subpopulation. (B)
LDLr-/-, TLR4-/-, and MyD88-/- mice were infused with saline (n=5) or AngII
(n=5-10) for 2 weeks while being fat-fed. Peripheral blood monocytes were
subdivided as described above. *P<0.01 LDLr-/- saline versus AngII MannWhitney rank sum.
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Figure 5.10: Development of AngII-induced atherosclerosis and AAAs are
attenuated by MyD88 deficiency in bone marrow-derived cells. (A)
Atherosclerotic lesion area was measured on aortic arch and thoracic intimal
surfaces and taken as a percentage of total arch and thoracic area. (B)
Measurements of maximal external width of abdominal aortas (mm). Clear
circles (MyD88+/+ bone marrow donor) and gray circles (-/- bone marrow donor)
represent individual mice, diamonds represent means, and bars are SEMs.
*P<.006 Mann-Whitney Rank Sum analysis MyD88+/+ vs -/- arch and thoracic
atherosclerosis. #P<.001 Fisher’s Exact Test MyD88+/+ vs -/- abdominal aortic
width.
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Figure 5.11: Development of AngII-induced vascular pathology does not
require the presence of TLR4 in bone marrow-derived cells. (A)
Atherosclerotic lesion area was measured on aortic arch and thoracic intimal
surfaces and taken as a percentage of total arch and thoracic area. (B)
Measurements of maximal external width of abdominal aortas (mm). Clear
circles (TLR4+/+) and gray circles (-/-) represent individual mice, diamonds
represent means, and bars are SEMs.
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5.5

Discussion:
This study examined the link between the main effector of the renin

angiotensin system, AngII, and the toll pathway in regards to vascular pathology.
We show that AngII can similarly upregulate TLR2, TLR4, and CD14 mRNA
expression in both vascular smooth muscle cells and macrophages.263,264 The
data also demonstrates up regulation of a crucial intracellular adaptor protein,
MyD88, localized to macrophages, but not vascular cells. Unpublished results
also confirm AngII up regulation of these 4 toll pathway components in mature
dendritic cells. The up regulation of MyD88 expression in activated macrophages
and dendritic cells may suggest this adaptor protein has increased activity in cells
of hematopoietic origin versus vascular-derived cells. TLR4 and MyD88 proteins
were also found to be colocalized to macrophages in AngII-induced
atherosclerotic lesions and AAAs. Previous data shows colocalization of TLR2
and TLR4 to macrophages in human and murine atherosclerotic lesions,
however, this is the first link to AAAs.223,228 These data suggest AngII can
upregulate toll pathway components and that these proteins are present in AngIIinduced vascular disease.
This study also demonstrated significant attenuation of AngII-induced
aortic arch and thoracic atherosclerosis using gene-targeted deletions of the toll
pathway receptors TLR2 (Figure 5.6A) and TLR4 (Figure 5.7A), as well as their
major signaling subunit MyD88 (Figures 5.4A and 5.5A). These results confirm
numerous demonstrations of MyD88, TLR2, and TLR4 attenuating the
progression of atherosclerosis in long-term fat feeding studies, using an apoE-/background.146,236,237 However, apoE is known to have many anti-atherogenic
and anti-inflammatory effects, possibly mediated through regulation of plasma
cholesterol homeostasis and immunomodulation.265-267 Deficiency of apoE also
upregulates responsiveness and activation, specifically of TLR4 and TLR3.262
Therefore, we bred out the apoE component and crossed the MyD88 mice onto
an LDLr-/- background to confirm our results. All results obtained in the apoE-/108

strain were also demonstrated in the LDLr-/- strain, suggesting no complications
in regards to data interpretation. We also show no changes in TLR2 or TLR4
attenuations of atherosclerosis in the LDLr-/- strain, confirming a previous fat
feeding study in TLR2 x LDLr animals.147 These data also show that the AngII
accelerated model of atherosclerosis induces similar correlative results to long
term diet studies in the short span of 5 weeks.
The present study also demonstrates the novel involvement of the toll
pathway in the development of AngII-induced AAAs. Specifically, deletion of
MyD88, in both an apoE-/- and LDLr-/- background, significantly attenuates the
formation of abdominal dilation, aortic arch area increases, aortic arch aneurysm,
AAAs, and incidence of rupture-induced death (Figure 5.4 and 5.5, Table 5.1 and
5.2). We further show that TLR4 deficiency also significantly attenuates the
formation of suprarenal abdominal dilation, aortic arch aneurysm, and AAAs
(Figure 5.7 and Table 5.2). However, TLR4 deficiency had no effect on ruptureinduced death, or aortic arch area. Furthermore, infusion of 19 TLR4-/- mice with
AngII led to one mouse with AAA at the end of 28 days. Out of the five TLR4-/AAAs, four of them were rupture-induced deaths occuring rapidly in the first week
of infusion. As shown in Table 5.3, TLR4-/- bone marrow results in a significant
deficit in platelet numbers, suggesting these mice may develop
thrombocytopenia contributing to the inability to withstand aneurysm rupture in
these mice. Other studies have confirmed lower basal platelet numbers in TLR4
deficient animals, however, basal levels have not been verified in our deficient
animals.268. TLR2 deficiency, while having a role in atherosclerosis, did not affect
a change in AngII-induced aneurysms (Figure 5.6 and Table 5.2). These data
suggest that TLR4 mediates signaling of MyD88 to induce arch aneurysm and
AAA formation.
Recently published studies have suggested TLR4 mediates insulin
resistance and lipid-induced activation of inflammatory pathways.269,270 Results
have shown fat-fed animals have increases in both expression and signaling of
toll receptors in adipose tissue. It has also been demonstrated that TLR4-/- mice
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develop diet-induced obesity, to a higher extent than wild type animals, without
the up regulation in inflammatory cytokines, adipose macrophages, or
complications of diabetes.269,270 Our results confirm this data, insomuch as fatfed TLR4-/- mice have a trend for increased body and fat pat weights. The mice
in this study were fed a 21% saturated fat-enriched diet for 5 weeks, which could
account for the difference in results. However, we show that MyD88-/- animals,
fed a high fat diet, have a significant increase in body and fat pad weight,
resulting in over a 100% increase in adipocity index. Despite this increase in fat
mass, blood monocyte and inflammatory cell levels (Figure 5.8), and AngIIinduced pathologies remain at low levels. This study did not specifically examine
the role of diabetes or insulin resistance, however, insulin levels were recorded at
time of termination (unpublished data). These levels suggest a trend for
decrease in MyD88-/- (+: 101mg/dL, -: 91mg/dL) and TLR4-/- (+: 93mg/dL, -:
83mg/dL) mice, despite increased body weight and fat masses. This suggests
the MyD88 adaptor protein may also play an important role in insulin resistance
and lipid induced activation of inflammatory pathways.
MyD88 deficiency resulted in stagnant levels of white cells after AngII
infusion, and significantly attenuated levels of blood monocytes after fat feeding
(Figure 5.8). This data supports a hypothesis presented by Bjorkbacka et al.,
suggesting MyD88 deficiency has defects in macrophage activation.146 This also
supports a role for MyD88 in circulation of monocytes and macrophages, which
are key mediators of atherosclerosis and aneurysm formation. Therefore, we
ascertained the role of the hematopoietic cells by performing a bone marrow
transplantation using MyD88+/+ irradiated recipients injected with MyD88+/+ and
-/- bone marrow-derived donor cells. The results demonstrate that MyD88+/+
repopulation with MyD88-/- cells leads to a significant decrease in aortic arch and
thoracic atherosclerosis (Figure 5.9). However, the decrease in aortic arch
atherosclerosis, in MyD88-/- bone marrow-derived cells (34%), is much less than
the whole body deficiency of MyD88 (apoE-/- 82%; LDLr-/- 64%), suggesting a
possible role for recipient MyD88, which was not examined in this study. Similar
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to whole body deficiency experiments, MyD88-/- bone marrow derived-cells
significantly attenuated the formation of suprarenal aortic diameter, arch area
increases, arch aneurysm incidence, and AAA incidence. These data suggest
MyD88, in hematopoietic populations, are important to the formation of AngIIinduced atherosclerosis and critical to aneurysm formation.
To confirm whole body experiments, TLR4 was also examined via bone
marrow transplantation using TLR4+/+ irradiated recipients injected with TLR4+/+
and -/- bone marrow-derived donor cells. Surprisingly, TLR4-/- donor cells did
not recapitulate the whole body studies, as there was no change in regards to
AngII-induced atherosclerosis or aneurysm formation. Previous studies have
demonstrated TLR2 deficiency also had no effects on atherosclerosis when
TLR2+/+ recipients were irradiated and injected with TLR2-/- marrow-derived
cells. Other studies suggest that endothelial cell TLR2 is responsible for the
reductions in atherosclerosis. In a published abstract, Mullick et al. also
demonstrates TLR4-/- bone marrow has no effect on atherosclerosis in a longterm fat feeding study, which confirms our data. These data suggest that TLR4
does not mediate the bone marrow-induced effects of MyD88.
Further work will be necessary to characterize these differences.
However, it is possible that MyD88 is important on hematopoietic cells, such as
monocytes and macrophages, which are critical for initiation of these pathologies.
With the defects in macrophage populations we speculate that the function of
these cells are diminished and therefore a reduction in vascular pathology
ensues. However, it is very important to note that TLR4 deficiency does not
share these decreases in monocyte populations with MyD88. This, therefore,
suggests that TLR4 might play a critical role in endothelial or smooth muscle
cells for further progression of atherosclerosis and aneurysm disease processes.
Therefore, we speculate that macrophages deficient in MyD88 do not require
TLR4 due to their inability to become initially activated. However, without TLR4,
it appears MyD88 can still become activated and progress disease on
monocyte/macrophages. It remains to be tested whether deficiency of TLR4 on
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endothelial and SMCs would ablate the progression of these diseases.
In conclusion, the present study demonstrated the presence of the adaptor
protein MyD88 in marrow-derived cells is critical for induction of AngII-induced
vascular disease. However, studies with TLR4 deficiency only reciprocate
experiments with whole body deficient MyD88. Future studies will define the
relative role of MyD88 in marrow-derived cells in the initiation of disease, and
TLR4 in resident cells in the progression of pathology.

Copyright © Albert Phillip Owens III 2008
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Chapter Six: Discussion and Future Directions

Natural progression of thesis (Disclaimer):
The purpose of this thesis was to try and ascertain the relative regional
effects of Angiotensin II on the aortic vasculature. The rationale for this was to
try and determine a morphological causality for the formation of AAA localized to
the suprarenal aorta. However, during the course of the examination of the
vasculature, we determined there to be no obvious difference between the
suprarenal aorta and anterior thoracic aortic sections in regard to morphological
assembly in vivo. This resulted in the production of a new project, to analyze the
various portions of the aorta, in a more in-depth manner and characterize these
results in the literature. During this documentation process, we tried to
characterize contractility in these various segments, only to find that AngII did not
lead to any significant contractions in either the thoracic or suprarenal aorta.
This was a surprising result, as it has been reported more than a few times that
AngII caused abdominal contractions. We then extended this study to the
infrarenal aorta, when we found that this area of the vasculature is what was
interpreted as ‘abdominal aorta’ in the literature. This led to a segmentation of
these two projects and an expansion in aortic characterizations to include the
entire aorta (aortic arch and infrarenal aortas were now included in the analysis).
This inclusion of the aortic arch led to the discovery of regional hyperplasia,
versus the remainder of the aortas hypertrophic response to AngII. In searching
for a mechanism, I happened to catch a lecture at the ATVB meeting in 2005 by
Coleen McNamara, about the role of AngII and redox control of Id3. We
subsequently obtained the Id3-/- mice and the result turned into our major finding
of the paper. Concurrent with these ‘morphology’ studies, I was also interested
in the main focus of the laboratory, that being AngII induction of atherosclerosis
and abdominal aortic aneurysm. With the reading of recent papers out of Moshe
Arditi’s UCLA group and Mason Freeman’s Harvard group describing the role of
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MyD88 and Toll receptors in fat-fed atherosclerosis, I thought there were many
similarities with this innate immune system and the causalities of AAA formation.
Then, and even to date, very few publications have examined the role of innate
immunity in aneurysm. The opportunity was given to me to present my ideas
involving MyD88 and AAA as a grant for my qualifying examination in order to get
the project, and luckily, I must have struck a cord somewhere, for soon after I
was writing an AHA grant on the subject and we were in the process of obtaining
MyD88-/- mice from Harvard.
While it is a difficult task to link these three unique and different projects, I
eventually came to the conclusion that although separate, this thesis is
connected by the original hypothesis of regional differences in regard to AngII.
The morphology project (Chapter 2) has regional effects of AngII in the aortic
arch leading to hyperplasia versus the hypertrophy found in the remainder of the
aorta. The contractility project (Chapter 3) finds regional induction of AngII
contraction highly localized to the infrarenal aorta. The MyD88 atherosclerosis
and aneurysm project (Chapter 5) finds a characterized reduction of aneurysm in
the suprarenal aorta. This project connects three disparate studies into the
regional effects of AngII.
A. Chapter 2 Discussion and Future Directions.
Chapter 2 demonstrated that AngII promoted a uniform medial expansion
throughout the aorta. The following characterization of this expansion led to the
underlying finding of the paper: SMC hyperplasia in the ascending aorta, and
SMC hypertrophy in all other aortic regions. This effect was due to stimulation of
AT1a receptors, but independent of increases in SBP. AngII-induced medial
expansion was ablated in all aortic regions in mice with functional deficiency of
p47phox, while the hyperplastic response localized to the ascending aorta was
inhibited by deficiency of Id3.
The novelty of this chapter is in the demonstration that AngII infusion
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promotes aortic medial expansion by disparate mechanisms in a region-specific
manner. A major difference was the demonstration of the disparity of responses
in the ascending aorta compared to other regions. Unique responses of this
region in aortic lumenal expansion have also been demonstrated in mice
harboring fibrillin-1 mutations and during AngII infusion.170 Although this study
defined AngII-induced changes in SMCs, this effect could be directly on SMCs or
indirectly from another cell type. For example, endothelial cells secrete a wide
range of products that directly affect SMC function. Thus, subsequent studies will
delete the AT1a receptor in either endothelium or SMCs to determine whether
AngII is exerting its effects by an action directly on SMCs.
We have recently found that AT1a SMC depletion using cre-lox technology
demonstrated no changes in AngII-induced medial thickening. These mice show
uniform medial expansion similar to the normal C57BL/6 aortas dissected and
analyzed for Chapter 2. This result leads us to believe that endothelial-specific
AT1a might be responsible for medial thickening. This would be a most
interesting finding, since it is the SMC in the aortic wall affected by AngII infusion
in the current study. When re-examining tissue sections, it is near impossible to
detect any difference in the small amount of endothelia that remains on the
sections. This may be due to the continual perfusion or fixation process that was
undertaken for nearly 30 minutes of constant flow. Therefore, the deletion of
endothelial AT1a, using a Tie2 promoter, will hopefully give us insight into the
formation of this SMC pathology. However, there is also a possibility that the
endothelial specific depletion might also yield us no results. If this is the case,
then an examination of the adventitial AT1a might be warranted. Another
possibility exists that this effect requires a combination of many different cell
types acting in unison for this SMC effect. In that rare case, it might be possible
to tease out the effects using cell culture systems using transmembrane cultures
of endothelial cells and SMCs and varying depletion of AT1a in either cell type to
detect changes in SMCs when treated with AngII.
Another interesting area to examine further would be the interaction of
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AngII and Id3. When this paper is published, it will only represent the third paper
in the literature connecting the RAS with Id3. An interesting question that has not
yet been answered is why is Id3 so concentrated in the aortic arch of C57BL/6
mice? Another interesting result, that will go unreported, was that of the eight
Id3-/- mice infused with AngII, one of them died of AAA rupture, and two others
developed extremely large AAAs. With the recent publication of p21 involvement
in AngII-induced AAA, and Id3 being intimately connected with the regulation of
p21, this may be an interesting area of study.271
B. Chapter 3 Discussion and Future Directions.
Chapter 3 demonstrated that AngII promotes region-specific contractions
limited to the infrarenal aortic vasculature. To examine the molecular basis of
this effect, angiotensin receptors were quantified and found to be concentrated in
the infrarenal aorta, with AT1bRs being the most abundant. AngII-induced
infrarenal contractions were ablated only in the AT1bR-/- mouse defining this
receptor subtype as the sole mediator of murine aortic contractions.
The novelty of this study is the demonstration that AngII incubation of
aortic sections can lead to a robust and regional contraction localized solely to
the infrarenal vasculature. This response was directly propegated from smooth
muscle cells and did not involve endothelial cells. This study provides direct
evidence that AT1bR’s mediate this contraction through disparate mechanisms of
the homologue, AT1a.
One interesting area of future study involves a connection I made in the
literature in Chapter 3's discussion section. This difference was between amino
acid 312 of the C-terminus which is present as an argenine in AT1b receptors
and a tyrosine in AT1a receptors.52 This Tyr to Arg switch possibly leads to a
ineffective Gq coupling and activation site in AT1b receptors versus the AT1a
subtype. This represents only one reason why AT1a and AT1b receptors differ
between each other, and also a major gap in the literature. It is still not yet clear
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why there are differences between these very homologous receptors, and I
believe this to be an interesting area of study.
Another result suggested AT1a receptors mediate effects through direct
action on smooth muscle cells (postjunctional), while AT1b receptors mediate
effects through indirect facilitation of norepinephrine on smooth muscle.175 Other
studies providing a possible cross-talk pathway between "/$ adrenergic
receptors and AT1 receptors. An interesting hypothesis might be that AT1b
concentration in the infrarenal aorta leads to activation by AngII and subsequent
release of norepinephrine release resulting in aortic contraction. The test of this
hypothesis would be simple enough and would require alpha/beta adrenergic
antagonism before addition of AngII into the culture bath. Further, if this
hypothesis is correct, the addition of adrenal glands in close proximity to the
aorta in the contraction bath would lead to a highly significant increase in
contractile properties. This would possibly prove that the infrarenal aortas
proximity to the adrenal glands could lead to even more stimulation of
contraction.
This is my chance to express my wild theories about the possible
involvement of AT1b in the role of AngII-induced AAA, so I’m going to take it and
run. I have been trying to associate a role of in vivo contraction with the
production of AngII-induced AAA localized to the suprarenal aorta. Our results
suggest that AngII-induction of contraction is all but absent in the suprarenal
aorta, and thus likely mediates minimal effects in abdominal aortic aneurysm
formation, in the AngII infusion model. However, another extremely interesting
result is the noticed formation of aneurysms everywhere throughout the aorta
(arch, thorax, suprarenal) with the exception of an absolute lack of AAA formation
to the infrarenal aorta, the sole mediator of AngII-induced contraction. It might be
that AT1b mediated contractions are creating more turbulent flow in a region that
probably already has plenty due to the enormity of branch points. An interesting
way to test whether AT1b mediation of contraction is mediating the concentration
of AAAs to the suprarenal aorta would be to take AT1bR-/- mice and infused
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them with AngII, or backcross them onto a hyperlipidemic background and
compare the results to the AT1a studies.
C. Chapter 5 Discussion and Future Directions
Chapter 5 examined the link between the main effector of the renin
angiotensin system, AngII, and the toll pathway in regards to vascular pathology.
We demonstrated that AngII can similarly upregulate TLR2, TLR4, and CD14
mRNA expression in both vascular cells and macrophages, verifying and
expanding a paucity of studies.263,264 This study also demonstrated significant
attenuation of AngII-induced aortic arch and thoracic atherosclerosis using genetargeted deletions of the toll pathway receptors TLR2 (Figure 4.6) and TLR4
(Figure 4.7), as well as their major signaling subunit MyD88 (Figures 4.4 and 5).
These results confirm numerous demonstrations of MyD88, TLR2, and TLR4
attenuating the progression of atherosclerosis in long-term fat feeding studies,
using an apoE-/- background.146,236,237 Attenuation of AngII-induced AAA was
demonstrated by the ablation of TLR4 and MyD88, while TLR2 was ineffective at
attenuating pathology. Furthermore, we demonstrated a link between the MyD88
gene and obesity studies in the literature examining TLR4, suggesting these
obesity characteristics are MyD88 dependent. Lastly, we found a role for MyD88
deficiency in bone marrow-derived cells in the induction of both AngII-induced
pathologies, while TLR4 deficiency in marrow-derived cells had no effect.
Therefore, the present study novelly demonstrated the presence of the
adaptor protein MyD88 in marrow-derived cells is critical for induction of AngIIinduced vascular disease. However, studies with TLR4 deficiency only
reciprocate experiments with whole body deficient MyD88. Future studies will
define the relative role of MyD88 in marrow-derived cells in the initiation of
disease, and TLR4 in resident cells in the progression of pathology.
Further work will be necessary to characterize the differences in the
MyD88 and TLR4 bone marrow studies. It is possible that MyD88 is important on
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hematopoietic cells, such as monocytes and macrophages, which are critical for
initiation of these pathologies. With the defects in macrophage populations we
speculate that the function of these cells are diminished and therefore a
reduction in vascular pathology ensues. However, it is very important to note
that TLR4 deficiency does not share these decreases in monocyte populations
with MyD88. This, therefore, suggests that TLR4 might play a critical role in
endothelial or smooth muscle cells for further progression of atherosclerosis and
aneurysm disease processes. Therefore, we speculate that macrophages
deficient in MyD88 do not require TLR4 due to their inability to become initially
activated. However, without TLR4, it appears MyD88 can still become activated
and progress disease on monocyte/macrophages. This therefore suggests that
the mechanism of initiation involves macrophage/monocyte populations, but also
needs the presence of endothelial or SMCs. This hypothesis has been
somewhat verified in the studies by Cassis et al., where AT1a receptor deficiency
on bone marrow derived cells has no effect on the inhibition of AAA formation,
but has minor effects on atherosclerosis.41 Further, this study shows that the
ablation of AT1a in recipient cells attenuates atherosclerosis and AAA
independent of marrow-derived cells, suggesting a role for both cell types in
atherosclerosis. This may be similar to the result we are observing, with the
exception that MyD88 deficient bone marrow derived cells might have nothing to
do with the MyD88 pathway, but instead with defective macrophages. A reverse
bone marrow transplantation needs to be performed to verify the hypothesis that
the toll pathway initiates atherosclerosis and AAA via endothelial cells and SMCs
and not via marrow-dependent cells. Further studies should also be conducted
in regard to AngII regulation of blood monocytes and macrophages, and their
subsequent role in vascular disease.
D. Discussion Summary
This thesis describes the novel findings of region-specific effects in AngII119

induced morphological, contractile, and pathological changes. These studies
provide evidence that the aortic arch may have altered embryological origins
versus the remainder of the aorta, leading to region-specific hyperplasia.
Further, that the infrarenal aorta contains highly localized concentrations of AT1b
receptors, which potentially leads to consistent up regulation in AngII
contractions. Finally, that AngII may induce region-specific suprarenal AAA
formation via mediation of the innate immune toll pathway. With all science,
however, much more work is needed to expand our knowledge of these
phenomena and to further characterize the always elusive question: why?
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